Novel hydrolase and method for producing (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid using the same

By using a new hydrolase from a specific microorganism contacting dialkyl 2-vinylcyclopropane-1,1-dicarboxylic acid, the problems of low optical purity and high cost in the prior art are solved, and high efficiency is achieved , low-cost (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropane carboxylic acid production, suitable for the production of intermediates for hepatitis C therapeutic drugs.

CN111918969BActive Publication Date: 2024-11-19API CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980022337.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-03-30
Filing Date
2019-03-29
Publication Date
2024-11-19
Estimated Expiration
2039-05-23

AI Technical Summary

Technical Problem

The prior art is difficult to efficiently and at low cost to manufacture (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropane carboxylic acid with high optical purity, and large-scale separation devices are required during industrial manufacturing, resulting in high costs.

Method used

Using novel hydrolase derived from Rhodococcus genus D32, Pseudocarboxylic dioxane CB1190 and Microbacterium Chocolic microbacterium, through dianyl 2-vinylcyclopropane-1,1-dicarboxylic acid dianyl Contact of the base ester efficiently generates (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropane carboxylic acid with high optical purity, and is produced at low cost using the microorganism or cell culture solution of the enzyme.

Benefits of technology

Achieve high efficiency and low cost production of (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropane carboxylic acid, suitable for intermediate manufacturing of hepatitis C therapeutic drugs, reducing production Cost and equipment requirements.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002701423600000031
    Figure BDA0002701423600000031
  • Figure BDA0002701423600000041
    Figure BDA0002701423600000041
  • Figure BDA0002701423600000061
    Figure BDA0002701423600000061
Patent Text Reader

Abstract

The present invention provides a novel hydrolase capable of industrially producing (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid with high optical purity at high efficiency and low cost, and a production method using the enzyme.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a novel hydrolase (esterase) which can be used for the preparation of (1S, 2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid and its application. Background Art

[0002] (1S,2S)-1-Alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid is an intermediate useful in the production of various HCV NS3 protease inhibitors and the like that are being developed as therapeutic drugs for hepatitis C.

[0003] Non-patent Document 1, Patent Document 1, and Patent Document 2 describe methods for obtaining (1S,2S)-1-methoxycarbonyl-2-vinylcyclopropanecarboxylic acid by hydrolyzing dimethyl 2-vinylcyclopropane-1,1-dicarboxylate using an enzyme.

[0004] However, the optical selectivity of the enzyme used in Non-Patent Document 1 is insufficient, and the optical purity of the obtained (1S, 2S)-1-methoxycarbonyl-2-vinylcyclopropanecarboxylic acid is 90% ee, which is insufficient and not suitable for industrial production as a pharmaceutical intermediate. In addition, the optical selectivity of the enzyme used in Patent Documents 1 and 2 is insufficient, and in addition to the target (1S, 2S)-1-methoxycarbonyl-2-vinylcyclopropanecarboxylic acid, the amount of (1S, 2R)-1-methoxycarbonyl-2-vinylcyclopropanecarboxylic acid produced as a by-product is also large, so it is difficult to efficiently produce the target substance. In addition, in the case of industrial production, a large separation device and purification device are required, which increases the cost.

[0005] Therefore, a method for industrially producing (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid which is useful as an intermediate for the production of a hepatitis C therapeutic drug and the like is desired with high purity, high efficiency and low cost.

[0006] Prior art literature

[0007] Patent Literature

[0008] Patent Document 1: Japanese Patent No. 5613660

[0009] Patent Document 2: Japanese Patent No. 5657560

[0010] Non-patent literature

[0011] Non-patent document 1: C. Fliche et al. Synth. Commun. 24 (20), 2873-2876 (1994) Summary of the invention

[0012] Problems to be solved by the invention

[0013] The problem to be solved by the present invention is to provide a novel hydrolase (esterase) for producing (1S, 2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid with high optical purity and high selectivity. In addition, the problem to be solved by the present invention is to provide a novel method for industrially producing (1S, 2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid with high optical purity with high efficiency and low cost.

[0014] Methods used to solve problems

[0015] The present inventors have conducted intensive studies to solve the above-mentioned problems and have found that enzymes derived from Rhodococcus sp. D32 strain, Pseudonocardiadioxanivorans CB1190 strain and Microbacterium chocolatum can hydrolyze 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl esters with high selectivity to efficiently obtain (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid. In addition, it was found that by contacting the enzyme, a microorganism or cell having the ability to produce the enzyme, a processed product of the microorganism or cell, and / or a culture solution containing the enzyme obtained by culturing the microorganism or cell (hereinafter sometimes collectively referred to as "enzyme, etc.") with 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester, (1S, 2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid with high optical purity, high selectivity and high concentration can be obtained at low cost. It was further found that by using the (1S, 2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid obtained in this way, (1R, 2S)-1-amino-1-alkoxycarbonyl-2-vinylcyclopropane with high optical purity can also be produced efficiently and at low cost. The present invention is completed based on these insights.

[0016] That is, the present invention is as follows.

[0017] [1] A hydrolase comprising any one of the following polypeptides (a) to (e).

[0018] (a) A polypeptide having the amino acid sequence represented by SEQ ID NO: 2

[0019] (b) A polypeptide having an amino acid sequence represented by SEQ ID NO: 4 or 6 and having an activity of catalyzing the reaction represented by formula (1)

[0020]

[0021] (wherein R represents an alkyl group having 1 to 6 carbon atoms)

[0022] (c) A polypeptide having an amino acid sequence in which one or more amino acids are deleted, inserted, substituted and / or added to the amino acid sequence of SEQ ID NO: 2, 4 or 6, and having an activity of catalyzing the reaction represented by formula (1)

[0023] (d) A polypeptide having an amino acid sequence having a sequence identity of 60% or more to the amino acid sequence of SEQ ID NO: 2, 4 or 6, and having an activity of catalyzing the reaction represented by the above formula (1)

[0024] (e) A polypeptide having an amino acid sequence having a sequence identity of 60% or more to the amino acid sequence of SEQ ID NO: 2, 4 or 6, and having one or more motif sequences selected from the following motif sequences (i) to (iv) in the amino acid sequence.

[0025] (i) A sequence consisting of five consecutive residues (aspartic acid (D), alanine (A), threonine (T), arginine (R), and glycine (G))

[0026] (ii) A sequence consisting of four consecutive residues (proline (P), tyrosine (Y), glycine (G), and phenylalanine (F))

[0027] (iii) A sequence consisting of four consecutive residues (asparagine (N), tryptophan (W), proline (P), and glycine (G))

[0028] (iv) A sequence consisting of five consecutive residues (proline (P), glycine (G), tryptophan (W), proline (P), glycine (G))

[0029] [2] The hydrolase according to [1], wherein R in the formula (1) is an ethyl group.

[0030] [3] A nucleic acid encoding the hydrolase described in [1] or [2].

[0031] [4] The nucleic acid according to [3], wherein the nucleic acid comprises the base sequence shown in (f), (g), (h) or (i) below.

[0032] (f) The base sequence represented by SEQ ID NO: 1, 3 or 5

[0033] (g) A nucleic acid encoding a polypeptide having an activity of catalyzing the reaction represented by formula (1) wherein one or more bases are substituted, deleted and / or added in the base sequence represented by SEQ ID NO: 1, 3 or 5

[0034]

[0035] (wherein R represents an alkyl group having 1 to 6 carbon atoms)

[0036] (h) a nucleic acid having a base sequence having a sequence identity of 60% or more to the base sequence represented by SEQ ID NO: 1, 3 or 5, and encoding a polypeptide having an activity of catalyzing the reaction represented by the above formula (1)

[0037] (i) a nucleic acid encoding a polypeptide having an activity of catalyzing the reaction represented by the above formula (1) which hybridizes with the complementary strand of the base sequence represented by SEQ ID NO: 1, 3 or 5 under stringent conditions

[0038] [5] A method for producing (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid, comprising: contacting the hydrolase described in [1] or [2], a microorganism or cell capable of producing the above enzyme, a treated product of the above microorganism or cell, and / or a culture solution containing the above enzyme obtained by culturing the above microorganism or cell with a 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester represented by formula (I), thereby producing (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid represented by formula (II).

[0039] [6] The production method according to [5], wherein the microorganism or cell is a microorganism or cell transformed with the nucleic acid according to [3] or [4].

[0040] [7] A recombinant vector comprising the nucleic acid described in [3] or [4].

[0041] [8] A transformant, characterized in that it contains the recombinant vector described in [7].

[0042] Effects of the Invention

[0043] According to the present invention, a novel hydrolase (esterase) for producing (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid useful as an intermediate for producing a hepatitis C therapeutic drug, etc., with high optical purity and high selectivity can be provided. In addition, according to the present invention, a novel method for industrially producing (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid with high optical purity can be provided with high efficiency and low cost. In addition, by using the (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid obtained in this way, (1R,2S)-1-amino-1-alkoxycarbonyl-2-vinylcyclopropane with high optical purity can be produced with high efficiency and low cost.

[0044] The (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid produced by the method of the present invention and the (1R,2S)-1-amino-1-alkoxycarbonyl-2-vinylcyclopropane produced using the same can be used as a starting material or a production intermediate in the production of a therapeutic drug for hepatitis C, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 This is a graph showing the results of HPLC analysis of the reaction product obtained in Example 1 using bacterial cells having the amino acid sequence D32Est.

[0046] Figure 2 This is a diagram showing the results of HPLC analysis of a reaction product obtained using bacterial cells having the amino acid sequence PnbA3027-m26.

[0047] Figure 3 is a diagram showing an alignment of hydrolases. DETAILED DESCRIPTION

[0048] Hereinafter, the present invention will be described in detail.

[0049] 1. Hydrolase of the present invention

[0050] The hydrolase of the present invention is a hydrolase comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 2, 4 or 6, or a hydrolase comprising a polypeptide having an amino acid sequence having high identity with the amino acid sequence (hereinafter sometimes referred to as a "homolog of the amino acid sequence") and having activity of hydrolyzing diethyl 2-vinylcyclopropane-1,1-dicarboxylate (hereinafter sometimes referred to as a "homolog of the hydrolase"). Specifically, the novel hydrolase of the present invention comprises a polypeptide shown in (a), (b), (c), (d) or (e) below.

[0051] (a) A polypeptide having the amino acid sequence represented by SEQ ID NO: 2

[0052] (b) A polypeptide having an amino acid sequence represented by SEQ ID NO: 4 or 6 and having an activity of catalyzing the reaction represented by formula (1)

[0053]

[0054] (wherein R represents an alkyl group having 1 to 6 carbon atoms)

[0055] (c) A polypeptide having an amino acid sequence in which one or more amino acids are deleted, inserted, substituted and / or added to the amino acid sequence represented by SEQ ID NO: 2, 4 or 6, and having an activity of catalyzing the reaction represented by formula (1)

[0056] (d) A polypeptide having an amino acid sequence having a sequence identity of 60% or more to the amino acid sequence represented by SEQ ID NO: 2, 4 or 6, and having an activity of catalyzing the reaction represented by the above formula (1)

[0057] (e) A polypeptide having an amino acid sequence having a sequence identity of 60% or more to the amino acid sequence represented by SEQ ID NO: 2, 4, or 6, and having one or more motif sequences selected from the following motif sequences (i) to (iv) in the amino acid sequence:

[0058] (i) A sequence consisting of five consecutive residues (aspartic acid (D), alanine (A), threonine (T), arginine (R), and glycine (G))

[0059] (ii) A sequence consisting of four consecutive residues (proline (P), tyrosine (Y), glycine (G), and phenylalanine (F))

[0060] (iii) A sequence consisting of four consecutive residues (asparagine (N), tryptophan (W), proline (P), and glycine (G))

[0061] (iv) A sequence consisting of five consecutive residues (proline (P), glycine (G), tryptophan (W), proline (P), glycine (G))

[0062] In formula (1), as the alkyl group having 1 to 6 carbon atoms represented by R, linear or branched alkyl groups having 1 to 6 carbon atoms can be listed, and linear or branched alkyl groups having 1 to 3 carbon atoms can be listed more preferably. As specific examples, methyl, ethyl, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, tert-pentyl, neopentyl, n-hexyl and the like can be listed, among which methyl and ethyl are preferred, and ethyl is particularly preferred. It should be noted that the two Rs in formula (I) may be the same or different, and are preferably the same.

[0063] In the present invention, homologs of the hydrolase having the amino acid sequence represented by SEQ ID NO: 2, 4 or 6 include the polypeptide represented by (c), (d) or (e) above.

[0064] The polypeptide shown in (c) above is a polypeptide having an amino acid sequence obtained by deleting, inserting, replacing and / or adding one or more amino acids in the amino acid sequence represented by sequence number 2, 4 or 6, and having the activity of catalyzing the reaction shown in formula (1). In the case of substitution, it is preferred that one or more amino acids are conservatively substituted. In this specification, "conservative substitution of amino acids" refers to the substitution of amino acids with similar chemical properties, and examples thereof include substitution of basic amino acids with basic amino acids and substitution of acidic amino acids with acidic amino acids.

[0065] “One or two or more amino acids” means usually 1 to 100, preferably 1 to 50, more preferably 1 to 20, further preferably 1 to 10, and particularly preferably 1 to 5 amino acids.

[0066] The polypeptide represented by (d) above is a polypeptide having an amino acid sequence having a sequence identity of 60% or more to the amino acid sequence represented by SEQ ID NO: 2, 4 or 6, and having an activity of catalyzing the reaction represented by the above formula (1). Preferably, it is a polypeptide having an amino acid sequence having a sequence identity of 80% or more, more preferably 90% or more, and further preferably 95% or more to the entire length of the amino acid sequence represented by SEQ ID NO: 2, 4 or 6, and having an activity of catalyzing the reaction represented by the above formula (1).

[0067] The homology (also referred to as identity or similarity) of the amino acid sequences in this specification can be calculated using the homology calculation algorithm NCBI BLAST (National Center for Biotechnology Information Basic Local Alignment Search Tool), using, for example, the following conditions (expectation value = 10; gaps allowed; matrix = BLOSUM62; filter = OFF). Other algorithms for determining the homology of amino acid sequences include, for example, the algorithm described in Karlin et al., Proc. Natl. Acad. Sci. USA, 90: 5873-5877 (1993) [this algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) (Altschul et al., Nucleic Acids Res., 25:3389-3402 (1997))], Needleman et al., J. Mol. Biol., 48:444-453 (1970) [the algorithm is incorporated into the GAP program in the GCG software package], Myers and Miller, CABIOS, 4:11-17 (1988) [the algorithm is incorporated into the ALIGN program (version 2.0) which is part of the CGC sequence alignment software package], Pearson et al., Proc. Natl. Acad. Sci. USA, 85:2444-2448 (1988) [the algorithm is incorporated into the FASTA program in the GCG software package], etc., these algorithms can also be preferably used.

[0068] In the present invention, the activity of catalyzing the reaction represented by formula (1) refers to the activity of catalyzing the reaction of hydrolyzing 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester represented by formula (I) to produce (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid represented by formula (II).

[0069] Here, 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester has two stereoisomers, the (2R) isomer and the (2S) isomer. Unless under special conditions where stereo inversion at the 2-position occurs, basically only the (2S) isomer can be used as the raw material of the target (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid.

[0070] Therefore, the activity of catalyzing the reaction represented by formula (1) refers to the activity of catalyzing a reaction having the following selectivity: among the two alkoxycarbonyl groups bonded to the prochiral carbon at the 1-position of (2S)-2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester, only the pro-R alkoxycarbonyl group is preferentially hydrolyzed to preferentially generate (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid.

[0071] It should be noted that pro-R is a notation for distinguishing the two Xs present on CX2YZ, and the priority order is determined according to the CIP rule for each substituent on C. At this time, it is assumed that one of the two Xs has a higher priority than the other, and the relationship between their priorities with Y and Z remains unchanged. Based on the assumed priority order, the chirality of the central carbon is determined to be R or S by RS notation. In the case of R body, the preferred X at this time is taken as pro-R, and in the case of S body, it is taken as pro-S.

[0072] The selectivity can be confirmed by using the ratio of the (1S,2S) form to the (1R,2S) form of 1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid generated by hydrolysis as an index. The lower the amount of the (1R,2S) form generated compared to the amount of the (1S,2S) form generated, the higher the yield of (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid, which is more advantageous in terms of industrialization.

[0073] In addition, the generation ratio of the (1S, 2S) body and the (1R, 2S) body can be compared using the ratio of the generated Anti body to the Syn body as an indicator. Anti body and Syn body refer to geometric isomers, (1S, 2S) body and (1R, 2R) body are Anti bodies, and (1R, 2S) body and (1S, 2R) body are Syn bodies. In the present invention, the main component of the product obtained by hydrolysis is the (1S, 2S) body. Therefore, when quantifying the product, not only can an evaluation system that quantifies the (1S, 2S) body alone be used, but also an evaluation system that can separate the Anti body from the Syn body can be used to quantify the generation amount. That is, when quantifying the (1S, 2S) body, it can be replaced by quantifying the generation amount of the Anti body. Similarly, when quantifying the (1R, 2S) body, it can be replaced by quantifying the generation amount of the Syn body. The lower the rate of formation of the Syn form, the higher the yield of (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid, which is more advantageous in terms of industrialization.

[0074] These selectivities can be confirmed by the following method: a hydrolase or the like as a subject is brought into contact with a racemic 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester to produce 1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid, and the production amounts of the (1S,2S) form and (1R,2S) form of the produced 1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid are measured, or the production amounts of the Anti form and the Syn form are measured.

[0075] The contact method is not particularly limited, and examples thereof include adding a racemic 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester to a liquid containing the above-mentioned hydrolase as the object, and reacting it at an appropriate temperature (e.g., about 10° C. to about 45° C.) and pressure (e.g., about atmospheric pressure); and the like.

[0076] In addition, when the racemic 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester is hydrolyzed, the (2R) form may generate the (1S,2R) form and the (1R,2R) form when the (2R) form is hydrolyzed, and it is preferred to suppress the generation amount of the (1R,2R) form of the enantiomer corresponding to the target (1S,2S) form to a low level. Therefore, in the present invention, it is further preferred to have the following selectivity: among the two alkoxycarbonyl groups bonded to the prochiral carbon at the 1-position of (2R)-2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester, only the pro-R alkoxycarbonyl group is preferentially hydrolyzed to preferentially generate (1S,2R)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid. Similarly, it is further preferred to have the following selectivity: compared with (2R)-2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester, (2S)-2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester is preferentially hydrolyzed. Either selectivity can be measured by the enantiomeric excess (%ee) of the (1S,2S) form of 1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid generated by hydrolysis relative to the (1R,2R) form. The higher the enantiomeric excess of the (1S,2S) form, the less likely it is to adversely affect the subsequent manufacturing process and the physiological activity of the manufactured drug, and the more advantageous it is industrially.

[0077] The polypeptide shown in (e) above is a polypeptide having an amino acid sequence having a sequence identity of 60% or more with the amino acid sequence represented by SEQ ID NO: 2, 4 or 6, and having one or more motif sequences selected from the following motif sequences (i) to (iv) in the amino acid sequence.

[0078] (i) A sequence consisting of five consecutive residues (aspartic acid (D), alanine (A), threonine (T), arginine (R), and glycine (G))

[0079] (ii) A sequence consisting of four consecutive residues (proline (P), tyrosine (Y), glycine (G), and phenylalanine (F))

[0080] (iii) a sequence consisting of four consecutive residues (asparagine (N), tryptophan (W), proline (P), glycine (G)), and

[0081] (iv) A sequence consisting of five consecutive residues (proline (P), glycine (G), tryptophan (W), proline (P), glycine (G))

[0082] In the present invention, the motif sequence refers to a small structural part confirmed in the amino acid sequence of a polypeptide. It is known that in a class of polypeptides (proteins) that maintain a specific function, characteristic motif sequences exist in common. For example, it is known that in a specific type of hydrolase, serine (S), aspartic acid (D) and histidine (H) are amino acid residues required for catalytic activity (hydrolysis function). Specifically, the hydrolase RhEst1 shown in Catalysis Science and Technology, 2015, vol.5, 2622 has serine (S), aspartic acid (D) and histidine (H) as amino acid residues. In addition, as Figure 3 As shown, the hydrolase AFX20780 described in US Pat. No. 8,298,799 also has serine (S), aspartic acid (D), and histidine (H) as amino acid residues at specific positions.

[0083] like Figure 3 As shown, the amino acid sequence represented by sequence number 2, 4 or 6 of the present invention also has serine (S), aspartic acid (D) and histidine (H) at specific positions similar to the above-mentioned hydrolases RhEst1 and AFX20780, and has catalytic activity (hydrolysis function).

[0084] In addition, if Figure 3 As shown, the amino acid sequence represented by SEQ ID NO: 2, 4 or 6 of the present invention has one or more motif sequences selected from the following motif sequences (i) to (iv) as characteristic motif sequences.

[0085] (i) A sequence consisting of five consecutive residues (aspartic acid (D), alanine (A), threonine (T), arginine (R), and glycine (G))

[0086] (ii) A sequence consisting of four consecutive residues (proline (P), tyrosine (Y), glycine (G), and phenylalanine (F))

[0087] (iii) A sequence consisting of four consecutive residues (asparagine (N), tryptophan (W), proline (P), and glycine (G))

[0088] (iv) A sequence consisting of five consecutive residues (proline (P), glycine (G), tryptophan (W), proline (P), glycine (G))

[0089] These motif sequences are common to the amino acid sequences represented by SEQ ID NOs. 2, 4 or 6 of the present invention, except for the above-mentioned serine (S), aspartic acid (D) and histidine (H), and therefore it is presumed that these motif sequences are motif sequences required for the characteristic function of the enzyme of the present invention having the amino acid sequence, i.e., stereoselective hydrolysis of 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester. These motif sequences may function alone, or may function as desired by a plurality of motif sequences acting simultaneously.

[0090] As described above, the hydrolase of the present invention is a hydrolase comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 2, 4 or 6, or a hydrolase comprising a polypeptide having 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester hydrolysis activity as a homolog of the amino acid sequence. The degree of 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester hydrolysis activity of the hydrolase comprising a polypeptide having a homolog of the amino acid sequence may be quantitatively equivalent to that of the hydrolase comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 2, 4 or 6, or may be different within an allowable range (e.g., about 0.1 to about 5 times, preferably about 0.3 to about 3 times).

[0091] The amino acid sequences represented by sequence numbers 2, 4 and 6 are derived from Rhodococcus sp D32 strain, Pseudonocardia dioxanivorans CB1190 strain and Microbacterium chocolatum, respectively. The inventors have identified these amino acid sequences as hydrolases of dialkyl 2-vinylcyclopropane-1,1-dicarboxylate.

[0092] The polypeptide having the amino acid sequence represented by SEQ ID NO: 2 is a polypeptide derived from Rhodococcus sp D32 strain, which is a bacterium recovered from a soil sample. The amino acid sequence represented by SEQ ID NO: 2 was obtained by analyzing the N-terminal sequence of 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester hydrolase produced by the bacterium and analyzing the chromosomal DNA of Rhodococcus sp D32 strain.

[0093] The polypeptides having the amino acid sequences represented by sequence numbers 4 and 6 are sequences obtained from the genome information of the microorganisms from which they are derived. The amino acid sequences represented by sequence numbers 4 and 6 are respectively identical to the amino acid sequences GenBank accession numbers WP-013673631 and WP-053548180 encoded by DNA sequences predicted to encode proteins. There are no reports of actual existence of either of them being isolated or confirmed as proteins, and their functions as proteins are of course completely unknown.

[0094] In the present invention, among the polypeptides having the amino acid sequences represented by SEQ ID NOs: 2, 4 and 6, the polypeptide having the amino acid sequence represented by SEQ ID NOs: 2 is preferred because of the high yield and high selectivity of (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid.

[0095] The hydrolase of the present invention comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 2, 4 or 6 can also be obtained by purification and separation from Rhodococcus sp. D32 strain, Pseudonocardia dioxanivorans CB1190 strain and Microbacterium chocolatum, respectively, using a known method. Here, examples of purification methods include solvent extraction, distillation, column chromatography, liquid chromatography, recrystallization, and combinations thereof.

[0096] In addition, the lytic enzyme of the present invention can also be manufactured by culturing a transformant containing a nucleic acid encoding the lytic enzyme, and isolating and purifying the lytic enzyme from the resulting culture. The nucleic acid encoding the lytic enzyme of the present invention can be DNA, RNA, or a DNA / RNA chimera. DNA can be preferably cited. In addition, the nucleic acid can be double-stranded or single-stranded. In the case of double-stranded, it can be a double-stranded DNA, double-stranded RNA or a hybrid of DNA: RNA. In the case of single-stranded, it can be a sense strand (i.e., a coding strand) or an antisense strand (i.e., a non-coding strand).

[0097] As DNA encoding the hydrolase of the present invention, synthetic DNA etc. can be cited. For example, it can be obtained by the following method: using total RNA or mRNA fraction prepared from cells or tissues derived from Rhodococcus sp. D32 strain, Pseudonocardia dioxanivorans CB1190 strain or Microbacterium chocolatum as a template, directly amplifying by reverse transcriptase PCR, and converting the obtained full-length hydrolase cDNA by a known kit, such as MutanTM-super Express Km (TAKARA BIO INC.), MutanTM-K (TAKARA BIO INC.), etc., according to the ODA-LA PCR method, the gap duplex method, the Kunkel method or a method based on these methods. Alternatively, the total RNA or mRNA fragments can be inserted into appropriate vectors, cDNA can be cloned from the prepared cDNA library by colony hybridization, plaque hybridization, PCR, etc., and the cloned cDNA can be converted according to the above methods. The vector used in the library can be any one of phage, plasmid, cosmid, phasmid, etc.

[0098] As nucleic acids encoding polypeptides having an amino acid sequence represented by SEQ ID NOs. 2, 4 or 6, nucleic acids containing base sequences represented by SEQ ID NOs. 1, 3 or 5, respectively, can be cited. As long as a polypeptide having an activity of catalyzing the reaction represented by formula (1) is encoded, a nucleic acid containing a base sequence having a high consistency with the base sequence of SEQ ID NOs. 1, 3 or 5 (hereinafter sometimes referred to as a "homolog of nucleic acid") can also be used. That is, as nucleic acids encoding the polypeptide, nucleic acids having a base sequence represented by the following (f), (g), (h) or (i) can be cited.

[0099] (f) A nucleic acid having a base sequence represented by SEQ ID NO: 1, 3 or 5

[0100] (g) A nucleic acid having a base sequence obtained by replacing, deleting and / or adding one or more bases in the base sequence represented by SEQ ID NO: 1, 3 or 5, and encoding a polypeptide having an activity of catalyzing the reaction represented by the above formula (1)

[0101] (h) a nucleic acid having a base sequence having a sequence identity of 60% or more to the base sequence represented by SEQ ID NO: 1, 3 or 5, and encoding a polypeptide having an activity of catalyzing the reaction represented by the above formula (1)

[0102] (i) A nucleic acid having a base sequence that hybridizes with the complementary strand of the base sequence represented by SEQ ID NO: 1, 3 or 5 under stringent conditions and encoding a polypeptide having an activity of catalyzing the reaction represented by the above formula (1)

[0103] As homologs of the nucleic acid shown in (g) above, there can be cited nucleic acids that contain a base sequence obtained by deleting, replacing, inserting and / or adding one or more bases in the base sequence represented by sequence number 1, 3 or 5, and encode a polypeptide having the activity of catalyzing the reaction shown in the above formula (1). In the case of replacement, insertion or addition, it is preferred to replace, insert or add one or more bases. Here, "one or more bases" is, for example, 1 to 300, preferably 1 to 150, more preferably 1 to 60, further preferably 1 to 30, and particularly preferably 1 to 15 bases.

[0104] It should be noted that the base sequences represented by sequence numbers 1, 3, or 5 are base sequences obtained by optimizing the codons of the genes of the hydrolase RsD32Est (sequence number 2) derived from the D32 strain of Rhodococcus sp., the hydrolase PdEst (sequence number 4) derived from the CB1190 strain of Pseudonocardia dioxanivorans, and the hydrolase McEst (sequence number 6) derived from Microbacterium chocolatum for expression in Escherichia coli. Such DNAs in which the codons are optimized according to the host to be transformed are of course also included in the nucleic acids encoding the polypeptides having the activity of catalyzing the reaction represented by the above formula (1) that can be used in the present invention.

[0105] As homologs of the nucleic acid shown in (h) above, there can be mentioned nucleic acids having a base sequence having a sequence identity of 60% or more with the base sequence represented by SEQ ID NO: 1, 3 or 5, and encoding a polypeptide having an activity of catalyzing the reaction represented by the above formula (1). Preferably, it is a nucleic acid having a base sequence having a homology (also referred to as identity) of 80% or more, more preferably 90% or more, further preferably 95% or more, and further preferably 98% or more with the base sequence represented by SEQ ID NO: 1, 3 or 5, and encoding a polypeptide having an activity of catalyzing the reaction represented by the above formula (1).

[0106] The homology (also referred to as consistency) of the base sequence in this specification can be calculated using the homology calculation algorithm NCBIBLAST (National Center for Biotechnology Information Basic Local Alignment Search Tool, National Center for Biotechnology Information Basic Local Alignment Search Tool), using, for example, the following conditions (expected value = 10; gaps allowed; filtering = ON; match score = 1; mismatch score = -3). As other algorithms for determining the homology of base sequences, the homology calculation algorithm for amino acid sequences described above can be preferably exemplified.

[0107] As a homologue of the nucleic acid shown in (h) above, as long as it encodes a polypeptide having an activity of catalyzing the reaction shown in formula (1), it may be a nucleic acid that hybridizes under stringent conditions with the complementary strand of the base sequence of SEQ ID NO: 1, 3 or 5. Here, the "stringent conditions" can be appropriately set with reference to the conditions reported previously (e.g., Current Protocols in Molecular Biology, John Wiley & Sons, 6.3.16.3.6, 1999), and specifically, for example, the conditions of washing once, more preferably 2 to 3 times, at a salt concentration and temperature equivalent to the washing conditions of ordinary Southern hybridization, i.e., 60°C, 1×SSC, 0.1% SDS, preferably 0.1×SSC, 0.1% SDS, more preferably 65°C, 0.1×SSC, 0.1% SDS or 68°C, 0.1×SSC, 0.1% SDS (high stringency conditions) can be mentioned.

[0108] A person skilled in the art can obtain a homolog of the above-mentioned nucleic acid by appropriately replacing, deleting, inserting and / or adding the nucleic acid represented by SEQ ID NO: 1, 3 or 5 using site-directed mutagenesis (Nucleic Acids Res. 10, pp. 6487 (1982), Methods in Enzymol. 100, pp. 448 (1983), Molecular Cloning, PCR A Practical Approach IRL Press pp. 200 (1991)) and the like, and introducing the desired mutation.

[0109] The nucleic acid of the present invention can encode a polypeptide having an activity of catalyzing the reaction represented by the above formula (1). When the nucleic acid of the present invention has a base sequence represented by sequence number 1, 3 or 5, or a base sequence having a high identity with the base sequence represented by sequence number 1, 3 or 5, the degree of 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester hydrolysis activity of the hydrolase comprising the polypeptide encoded by the nucleic acid may be quantitatively equivalent to that of the hydrolase comprising the polypeptide having the amino acid sequence represented by sequence number 2, 4 or 6, or the hydrolase comprising the polypeptide having the homolog of the amino acid sequence, or may be different within an allowable range (e.g., about 0.1 times to about 5 times, preferably about 0.3 times to about 3 times).

[0110] In addition, based on the amino acid sequence of sequence number 2, 4 or 6 or a part thereof, or the base pair represented by sequence number 1, 3 or 5 or a part thereof, a homology search can be performed on a database such as the DNA Databank of JAPAN (DDBJ) to obtain the amino acid sequence information of a polypeptide having the activity of catalyzing the reaction represented by formula (1) or the base sequence information of the DNA encoding the polypeptide.

[0111] The hydrolase of the present invention has an activity of catalyzing the reaction represented by the above formula (1) with higher selectivity than the conventionally known hydrolase comprising the polypeptide shown in sequence number 24. In addition, when the hydrolase of the present invention hydrolyzes 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester, the production ratio of the (1S, 2R)-body, (1R, 2S)-body and / or (1R, 2R)-body of 1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid is low, and in particular, the production ratio of the (1S, 2R)-body, (1R, 2S)-body and / or (1R, 2R)-body is low compared to the hydrolase comprising the polypeptide shown in sequence number 24.

[0112] In the production method of the present invention described later, the above-mentioned hydrolase can be directly used for the reaction with 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester, but it is preferred to use a microorganism or cell having the ability to produce the enzyme, a treated product of the microorganism or cell, and / or a culture solution containing the enzyme obtained by culturing the microorganism or cell.

[0113] As the microorganism or cell with producing lytic enzyme of the present invention, it is possible to use the microorganism or cell that originally just has the ability of producing this lytic enzyme, or it is possible to give the microorganism or cell of above-mentioned production capacity by breeding.As microorganism or cell, no matter it is dead or alive, for example, dormant thalline etc. can be suitably used.As the microorganism or cell with producing lytic enzyme of the present invention, it is possible to enumerate the microorganism or cell described as " host microorganism " or " host cell " hereinafter.

[0114] As a method for imparting the above-mentioned production ability by breeding, known methods such as gene recombination treatment (transformation) and mutation treatment can be adopted. As a method of transformation, a method of introducing a target DNA, a method of modifying an expression control sequence such as a promoter on a chromosome to strengthen the expression of the target DNA, etc. can be cited.

[0115] Among these, microorganisms or cells transformed with the above-mentioned DNA encoding the polypeptide of the present invention are preferably used.

[0116] The nucleic acid (DNA) encoding the polypeptide (hydrolase) of the present invention can be cloned by using chromosomal DNA derived from Rhodococcus sp. D32 strain, Pseudonocardiadioxanivorans CB1190 strain or Microbacterium chocolatum as a template and performing PCR using appropriate primers as described above.

[0117] In addition, the nucleic acid (DNA) encoding the polypeptide (hydrolase) of the present invention can be cloned by using total RNA or mRNA derived from Rhodococcus sp. D32 strain, Pseudonocardia dioxanivorans CB1190 strain or Microbacteriumchocolatum as a template, directly amplifying by RT-PCR to prepare full-length hydrolase cDNA, and then performing PCR using appropriate primers.

[0118] For example, by inserting the DNA encoding the polypeptide of the present invention obtained as above into a known expression vector in a configuration capable of expression, a polypeptide gene expression vector of the present invention can be provided. Furthermore, by transforming a host cell using the expression vector, a transformant into which the DNA encoding the polypeptide of the present invention is introduced can be obtained. The transformant can also be obtained by integrating the DNA encoding the polypeptide of the present invention into the host's chromosomal DNA in a manner capable of expression using methods such as homologous recombination.

[0119] In this specification, "expression vector" is a genetic factor used to replicate and express a protein with a desired function in the host organism by inserting a polynucleotide encoding a protein with a desired function and introducing it into the host organism. Examples include plasmids, viruses, bacteriophages, cosmids, etc., but are not limited to these. Preferably, the expression vector is a plasmid.

[0120] In the present specification, the term "transformant" refers to a microorganism or cell into which a target gene has been introduced using the above-mentioned expression vector or the like, and which is capable of expressing a desired trait associated with a protein having a desired function.

[0121] As a method for making a transformant, specifically, a method of introducing a DNA encoding a polypeptide of the present invention into a plasmid vector, a phage vector or a viral vector stably present in a host cell, and introducing the constructed expression vector into the host cell can be exemplified; or the DNA is directly introduced into the host genome, and a method of transcribing and translating its genetic information. In this case, it is preferred that a suitable promoter is connected upstream of the 5'-side of the DNA in the host, and a terminator is further preferably connected downstream of the 3'-side. As such a promoter and terminator, as long as it is known that the promoter and terminator function in the cell used as the host, there is no particular limitation, and for example, the vector, promoter and terminator described in detail in "Microbiology Basic Lecture 8 Genetic Engineering·Kyoritsu Publishing" can be used.

[0122] The host microorganism to be transformed for expressing the hydrolase of the present invention is not particularly limited as long as the host itself does not adversely affect 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl esters and (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid, and examples thereof include the following microorganisms.

[0123] Bacteria for which a host-vector system has been established belong to the genera Escherichia, Bacillus, Pseudomonas, Serratia, Brevibacterium, Corynebacterium, Streptococcus, Lactobacillus, etc.

[0124] Actinomycetes belonging to the genera Rhodococcus and Streptomyces for which host-vector systems have been established.

[0125] Yeasts for which a host-vector system has been established belong to the genera Saccharomyces, Kluyveromyces, Schizosaccharomyces, Zygosaccharomyces, Yarrowia, Trichosporon, Rhodosporidium, Hansenula, Pichia, Candida, etc.

[0126] Fungi belonging to the genera Neurospora, Aspergillus, Cephalosporium, Trichoderma, etc., for which a host-vector system has been established.

[0127] The procedure for preparing transformants, the construction of recombinant vectors suitable for the host, and the host culture method can be carried out according to the conventional techniques in the fields of molecular biology, bioengineering, and genetic engineering (for example, the methods described in Molecular Cloning).

[0128] Preferred host microorganisms, preferred transformation methods in each microorganism, vectors, promoters, terminators, and the like are specifically listed below, but the present invention is not limited to these examples.

[0129] For Escherichia, especially Escherichia coli, plasmid vectors include pBR and pUC plasmids, promoters derived from lac (β-galactosidase), trp (tryptophan operon), tac, trc (fusion of lac and trp), lambda phage PL and PR, etc. In addition, terminators include terminators derived from trpA, phage, and rrnB ribosomal RNA.

[0130] For Bacillus, examples of vectors include pUB110 plasmids and pC194 plasmids, and integration into chromosomes is also possible. Promoters and terminators of enzyme genes such as alkaline protease, neutral protease, and α-amylase can be used.

[0131] For the genus Pseudomonas, examples of vectors include general host-vector systems established in Pseudomonas putida, Pseudomonas cepacia, etc., or broad-host vectors based on plasmids involved in the decomposition of toluene compounds and TOL plasmids (containing genes required for autonomous replication derived from RSF1010, etc.) pKT240 (Gene, 26, 273-82 (1983)), etc.

[0132] For Brevibacterium, in particular, Brevibacterium lactofermentum, examples of vectors include plasmid vectors such as pAJ43 (Gene 39, 281 (1985)). Various promoters and terminators used in Escherichia coli can be used as promoters and terminators.

[0133] For Corynebacterium, in particular, Corynebacterium glutamicum, examples of vectors include plasmid vectors such as pCS11 (Japanese Unexamined Patent Publication No. 57-183799) and pCB101 (Mol. Gen. Genet. 196, 175 (1984)).

[0134] For yeast (Saccharomyces), in particular, Saccharomyces cerevisiae, examples of vectors include YRp-based, YEp-based, YCp-based, and YIp-based plasmids, etc. In addition, promoters and terminators of various enzyme genes such as alcohol dehydrogenase, 3-glyceraldehyde-phosphate dehydrogenase, acid phosphatase, β-galactosidase, phosphoglycerate kinase, and enolase can be used.

[0135] For the genus Schizosaccharomyces, examples of vectors include plasmid vectors derived from Schizosaccharomyces pombe described in Mol. Cell. Biol. 6, 80 (1986) and the like. In particular, pAUR224 is commercially available from Takara Bio Co., Ltd. and can be easily used.

[0136] Aspergillus genus, Aspergillus niger, Aspergillus oryzae, etc. are the most studied among molds, and plasmids or integration into chromosomes can be used, and promoters derived from extracellular proteases or amylases can be used (Trends in Biotechnology 7, 283-287 (1989)).

[0137] In addition to the above, host-vector systems corresponding to various microorganisms have been established, and these host-vector systems can be used appropriately.

[0138] In addition, in addition to microorganisms, various host / vector systems have been established in plants and animals. In particular, systems for expressing large amounts of different types of proteins in animals such as insects (e.g., silkworms) (Nature 315, 592-594 (1985)) and plants such as rapeseed, corn, and potatoes, as well as cell-free protein synthesis systems using Escherichia coli cell-free extracts or wheat germ, have been established and can be appropriately utilized.

[0139] Examples of treated products of microorganisms or cells having the ability to produce the hydrolase of the present invention include treated products obtained by treating the microorganisms or cells with an organic solvent or surfactant such as acetone, dimethyl sulfoxide (DMSO), toluene, etc., treated products obtained by freeze-drying, treated products obtained by physical or enzymatic disruption, cell preparations such as treated products, treated products obtained by extracting the enzyme fraction in the microorganisms or cells in the form of a crude or purified product, and treated products obtained by further fixing them on a carrier represented by polyacrylamide gel, carrageenan, etc.

[0140] Examples of the culture solution containing the enzyme obtained by culturing a microorganism or cell having the ability to produce the hydrolase of the present invention include a suspension of the cells and a liquid culture medium, and, when the cells are secretory expression cells, a supernatant obtained by removing the cells by centrifugation or the like, or a concentrate thereof.

[0141] 2. Compositions of the present invention

[0142] The composition (enzyme agent) of the present invention comprises the hydrolase of the present invention, a microorganism or cell having the ability to produce the enzyme, a processed product of the microorganism or cell, and / or a culture solution containing the above enzyme obtained by culturing the microorganism or cell, and catalyzes the reaction of generating (1S, 2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid using 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester as a substrate. By using the composition of the present invention as a catalyst, it is possible to efficiently and inexpensively produce (1S, 2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid with high optical purity industrially, and therefore it is useful.

[0143] In the composition of the present invention, in addition to the active ingredients (enzymes, etc.), excipients, buffers, suspending agents, stabilizers, preservatives, preservatives, physiological saline, etc. can also be contained. As excipients, lactose, sorbitol, D-mannitol, white sugar, etc. can be used. As buffers, phosphates, citrates, acetates, etc. can be used. As stabilizers, propylene glycol, ascorbic acid, etc. can be used. As preservatives, phenol, benzalkonium chloride, benzyl alcohol, chlorobutanol, methyl parahydroxybenzoate, etc. can be used. As preservatives, benzalkonium chloride, parahydroxybenzoic acid, chlorobutanol, etc. can be used.

[0144] 3. Production of a carboxylic acid monoester represented by the following formula (II') using the hydrolase of the present invention

[0145] According to the present invention, a method for producing a carboxylic acid monoester represented by the following formula (II') can be provided, the method comprising the production represented by formula (2), that is, allowing the hydrolase of the present invention to act on a dicarboxylic acid ester represented by the following formula (I') to produce a carboxylic acid monoester represented by the following formula (II').

[0146]

[0147] (wherein R' represents an optionally substituted alkyl group having 1 to 10 carbon atoms, an aralkyl group having 7 to 20 carbon atoms, or an aryl group having 6 to 12 carbon atoms)

[0148] In formula (2), as the "alkyl group of 1 to 10" in the "alkyl group of 1 to 10 carbon atoms which may be substituted" represented by R', examples include linear, branched or cyclic alkyl groups of 1 to 10 carbon atoms, and more preferably linear, branched or cyclic alkyl groups of 1 to 6 carbon atoms. Among these, preferably, for example, methyl, ethyl, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, tert-pentyl, neopentyl, n-hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like are mentioned, and alkyl groups of 1 to 4 carbon atoms are more preferred, and linear or branched alkyl groups of 1 to 4 carbon atoms are further preferred, and ethyl is particularly preferred. Examples of the substituent in the "optionally substituted alkyl group having 1 to 10 carbon atoms" include a halogen atom (e.g., a chlorine atom, a bromine atom), a linear or branched alkoxy group having 1 to 6 carbon atoms (e.g., a methoxy group, an ethoxy group), and a nitro group.

[0149] The "aralkyl group having 7 to 20 carbon atoms" in the "aralkyl group having 7 to 20 carbon atoms which may be substituted" represented by R' is preferably an aralkyl group having 7 to 12 carbon atoms. Among these, benzyl, 2-phenylethyl, 1-phenylethyl, 3-phenylpropyl, etc. can be mentioned. As the substituent in the "aralkyl group having 7 to 20 carbon atoms which may be substituted", halogen atoms (such as chlorine atoms and bromine atoms), straight-chain or branched alkyl groups having 1 to 6 carbon atoms (such as methyl and ethyl), straight-chain or branched alkoxy groups having 1 to 6 carbon atoms (such as methoxy and ethoxy), etc. can be mentioned. As the "aralkyl group having 7 to 20 carbon atoms which may be substituted", benzyl, 4-methylbenzyl, 4-methoxybenzyl, 4-chlorobenzyl, 4-bromobenzyl, 2-phenylethyl, 1-phenylethyl, 3-phenylpropyl, etc. can be preferably mentioned.

[0150] Examples of the "aryl group having 6 to 12 carbon atoms" in the "aryl group having 6 to 12 carbon atoms which may be substituted" represented by R' include phenyl, 1-naphthyl, 2-naphthyl, etc. Examples of the substituent in the "aryl group having 6 to 12 carbon atoms which may be substituted" include halogen atoms (e.g., chlorine atoms, bromine atoms), linear or branched alkyl groups having 1 to 6 carbon atoms (e.g., methyl groups, ethyl groups), linear or branched alkoxy groups having 1 to 6 carbon atoms (e.g., methoxy groups, ethoxy groups), and nitro groups. Preferred examples of the “optionally substituted aryl group having 6 to 12 carbon atoms” include phenyl, 1-naphthyl, 2-naphthyl, o-tolyl, m-tolyl, p-tolyl, o-methoxyphenyl, m-methoxyphenyl, p-methoxyphenyl, 2,3-dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2,3,5-trimethylphenyl, 2,3,6-trimethylphenyl, 2,4,6-trimethylphenyl, o-nitrophenyl, m-nitrophenyl and p-nitrophenyl.

[0151] R' is particularly preferably a methyl group, an ethyl group, a tert-butyl group or a benzyl group, and more preferably an ethyl group.

[0152] It should be noted that the two R's in formula (I') may be the same or different, but are preferably the same.

[0153] When the hydrolase of the present invention is brought into contact with the dicarboxylic acid diester represented by formula (I'), the carboxylic acid monoester represented by formula (II') can be produced by bringing the purified or crudely purified hydrolase of the present invention, a microorganism or cell having the ability to produce the hydrolase of the present invention (e.g., a transformant having a DNA encoding the polypeptide of the present invention, etc.), a treated product of the microorganism or cell, and / or a culture solution containing the enzyme obtained by culturing the microorganism or cell into contact with the dicarboxylic acid diester represented by formula (I').

[0154] The hydrolase of the present invention can be used directly in the reaction, but it is preferred to use a microorganism or cell having the ability to produce the enzyme, a treated product of the microorganism or cell, and / or a culture solution containing the enzyme obtained by culturing the microorganism or cell. Among these, it is preferred to use a transformant having a DNA encoding the polypeptide of the present invention.

[0155] Regarding the amount of the microorganism or cell added to the reaction solution, the treated product of the microorganism or cell, and / or the culture solution containing the enzyme obtained by culturing the microorganism or cell, when adding microorganisms or cells, the concentration of the microorganism or cell is usually about 0.1w / v% to about 50w / v%, preferably 1w / v% to 20w / v% based on the wet bacterial weight, and when using the treated product or culture solution, the specific activity of the enzyme is obtained, and the amount is added to reach the above-mentioned cell concentration. Here, w / v% means weight / volume%.

[0156] The dicarboxylic acid diester represented by the formula (I') which is a reaction substrate of the hydrolase of the present invention is usually used in the form of a (2S) compound or a racemic compound.

[0157] The reaction method is not particularly limited, and a dicarboxylic acid diester represented by formula (I') as a substrate can be added to a liquid containing the hydrolase of the present invention and reacted at an appropriate temperature and pressure (e.g., about atmospheric pressure). Thus, a carboxylic acid monoester represented by formula (II') can be produced.

[0158] The dicarboxylic acid diester represented by formula (I') as the reaction substrate is usually used in a substrate concentration range of 0.01 w / v% to 90 w / v%, preferably 0.1 w / v% to 30 w / v%. The reaction substrate may be added all at once at the start of the reaction, but is preferably added continuously or intermittently from the viewpoint of reducing the influence of substrate inhibition of the enzyme and increasing the accumulated concentration of the product.

[0159] The reaction is usually carried out in an aqueous medium or a mixture of an aqueous medium and an organic solvent. As the aqueous medium, for example, water or a buffer solution can be cited. As the organic solvent, methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, the tert-butyl alcohol, acetone, dimethyl sulfoxide, etc. can be used as solvents with high solubility for the dicarboxylic acid diester represented by the formula (I') as the reaction substrate. In addition, as the organic solvent, ethyl acetate, butyl acetate, toluene, chloroform, n-hexane, etc., which are effective for the removal of reaction byproducts, can also be used.

[0160] The reaction is carried out at a reaction temperature of usually 4 to 60°C, preferably 10 to 45°C, and at a pH of usually 3 to 11, preferably 5 to 8. The reaction time is usually about 1 to 72 hours.

[0161] The carboxylic acid monoester represented by formula (II') produced by the production method of the present invention can be separated from the bacteria, proteins, etc. in the reaction solution by separation or purification methods known to those skilled in the art such as centrifugation and membrane treatment after the reaction is completed, and then purified by an appropriate combination of extraction with an organic solvent such as 1-butanol and tert-butanol, distillation, column chromatography using ion exchange resins or silica gel, isoelectric crystallization, or crystallization using monohydrochloride, dihydrochloride, calcium salt, etc.

[0162] The hydrolase of the present invention can be particularly suitably used in a method for hydrolyzing diethyl 2-vinylcyclopropane-1,1-dicarboxylate to produce (1S,2S)-1-ethoxycarbonyl-2-vinylcyclopropanecarboxylic acid.

[0163] In addition, the dicarboxylic acid diester represented by the formula (I') as a substrate can be produced by the reaction of the following formula (3).

[0164]

[0165] (Where R 3 represents an arylsulfonyl group having 6 to 12 carbon atoms which may be substituted, an alkylsulfonyl group having 1 to 10 carbon atoms which may be substituted, or an aralkylsulfonyl group having 7 to 20 carbon atoms which may be substituted, and R' has the same meaning as above.)

[0166] That is, it can be produced by reacting a compound represented by formula (III) with a malonate represented by formula (IV) in the presence of an alkali metal alkoxide or an alkali metal hydride.

[0167] In formula (III), R 3 Examples of the "arylsulfonyl group having 6 to 12 carbon atoms" in the "arylsulfonyl group having 6 to 12 carbon atoms which may be substituted" include benzenesulfonyl, 1-naphthalenesulfonyl, 2-naphthalenesulfonyl, etc. Examples of the "alkylsulfonyl group having 1 to 10 carbon atoms" in the "alkylsulfonyl group having 1 to 10 carbon atoms which may be substituted" include methylsulfonyl, ethylsulfonyl, propylsulfonyl, etc. Examples of the "aralkylsulfonyl group having 7 to 20 carbon atoms" in the "aralkylsulfonyl group having 7 to 20 carbon atoms which may be substituted" include benzylsulfonyl, etc. Examples of the substituents in the "arylsulfonyl group having 6 to 12 carbon atoms which may be substituted", "alkylsulfonyl group having 1 to 10 carbon atoms which may be substituted" and "aralkylsulfonyl group having 7 to 20 carbon atoms which may be substituted" include halogen atoms (e.g., chlorine atoms, bromine atoms), linear or branched alkyl groups having 1 to 6 carbon atoms (e.g., methyl groups, ethyl groups), linear or branched alkoxy groups having 1 to 6 carbon atoms (e.g., methoxy groups, ethoxy groups), and nitro groups. 3Specific examples of suitable R include benzenesulfonyl, p-toluenesulfonyl, 1-naphthalenesulfonyl, 2-naphthalenesulfonyl, methylsulfonyl, ethylsulfonyl, propylsulfonyl, trifluoromethanesulfonyl and benzylsulfonyl. 3 Preferred are a methanesulfonyl group, a benzenesulfonyl group and a p-toluenesulfonyl group, and particularly preferred is a p-toluenesulfonyl group.

[0168] Here, the compound represented by formula (III) as the starting compound of formula (3) can be produced by a known method, for example, the method described in Frederic Dolle et al., Bioorg. Med. Chem. 2006, 14, 1115-1125, etc. Alternatively, it can be produced by the reaction of the following formula (4).

[0169]

[0170] That is, 1,4-butenediol (VI) and R 3 X (X represents a halogen atom such as a chlorine atom, a bromine atom, an iodine atom) to obtain a compound of formula (V) and crystallize it; or by hydrolyzing a commercially available raw material compound (VII) with an acid or a base to obtain 1,4-butenediol, and further reacting it with R 3 X reaction and crystallizing the obtained compound of formula (V).

[0171] In formula (4), X 1 Represents a hydrogen atom or R 1 , X 2 Represents a hydrogen atom or R 2 , R 1 and R 2 Each independently represents an alkylcarbonyl group having 2 to 11 carbon atoms, an aralkylcarbonyl group having 8 to 21 carbon atoms, or an arylcarbonyl group having 7 to 13 carbon atoms. 1 and X 2 When X is a hydrogen atom, 1 For R 1 And X 2 For R 2 From the viewpoint of being available as a commercial product, R 1 and R 2 All of them are acetyl groups, ethylcarbonyl groups, tert-butylcarbonyl groups or benzoyl groups, and more preferably all of them are acetyl groups.

[0172] By using the carboxylic acid monoester represented by formula (II') obtained in the present invention, it is possible to produce an intermediate (1R, 2S)-1-amino-1-ethoxycarbonyl-2-vinylcyclopropane (VIII) and a salt thereof which are useful in the production of various HCV NS3 protease inhibitors and the like in the development of therapeutic drugs for hepatitis C. Furthermore, by using the carboxylic acid monoester represented by formula (II') obtained in this way for production, it is also possible to produce (1R, 2S)-1-amino-1-alkoxycarbonyl-2-vinylcyclopropane having high optical purity efficiently and at low cost.

[0173]

[0174] Hereinafter, the present invention will be described in further detail using examples, but the present invention is not limited thereto.

[0175] Example

[0176] Example 1: Cloning of hydrolase genes

[0177] Using hydrolytic activity as an indicator, the soil sample was explored and the Rhodococcus sp. D32 strain was obtained. The new hydrolase RsD32Est (sequence number 2) was obtained based on the analysis of the hydrolase produced by this microorganism and the analysis of the gene information. Based on this amino acid sequence information, the gene sequence (sequence number 1) encoding RsD32Est, which was codon-optimized for expression in Escherichia coli, was artificially synthesized by DNA2.0 to obtain pJ411RsD32Est.

[0178] The DNA was synthesized by DNA2.0 and is encoded by Pseudonocardia dioxanivorans CB1190. The gene sequences (pedst_Ecodon, sequence number 3, mcest_Ecodon, sequence number 5 and afx20780_Ecodon) of the putative hydrolase PdEst (GenBank accession number WP_01367363, sequence number 4), McEst (GenBank accession number WP_053548180, sequence number 6) and hydrolase AFX20780 (GenBank accession number AFX20780, sequence number 8) from Escherichia coli (CB1190 strain), Microbacteriumchocolatum were codon-optimized for expression in Escherichia coli and inserted into pJExpress411 (manufactured by DNA2.0) to prepare plasmids (pJ411PdEst, pJ411McEst and pJ411AFX20780, respectively). The amino acid sequences encoded by the gene sequences were named RsD32Est, PdEst, McEst, and AFX20780. The amino acid sequences are shown in sequence number 2 (RsD32Est), sequence number 4 (PdEst), sequence number 6 (McEst), and sequence number 8 (AFX20780).

[0179] Using each plasmid obtained, Escherichia coli BL21 (DE3) (manufactured by Invitrogen) was transformed according to a conventional method to obtain recombinant Escherichia coli BL21 (DE3) / pJ411RsD32Est, BL21 (DE3) / pJ411PdEst, BL21 (DE3) / pJ411McEst and BL21 (DE3) / pJ411AFX20780. In order to obtain bacterial cells expressing the introduced genes, each recombinant Escherichia coli was cultured at 30° C. using a liquid LB medium containing kanamycin and lac promoter inducing substances, and the bacteria were collected about 20 hours after the culture.

[0180] E. coli clone No. 26 prepared in Reference Example 1 described later was also cultured at 30°C using a liquid LB medium containing kanamycin and a lac promoter inducing substance, and the bacteria were collected about 20 hours after the culture.

[0181] Example 2

[0182] Using each bacterial cell obtained in Example 1, it was reacted for 21 hours in a 100 mmol / L potassium phosphate buffer containing 30 g / L of racemic 2-vinylcyclopropane-1,1-dicarboxylic acid diethyl ester (hereinafter referred to as VCPDE) and 5% dimethyl sulfoxide at 30°C and pH 7. As each bacterial cell, a bacterial cell obtained by centrifugation from 0.4 mL of the culture solution prepared in Example 1 was used. It should be noted that VCPDE was synthesized according to the method described in the synthesis example of Japanese Patent No. 5657560.

[0183] After 20 hours of reaction, the reaction solution was diluted with acetonitrile to an appropriate concentration and analyzed by high performance liquid chromatography (HPLC) under the following conditions. Analysis conditions (1) are analysis conditions for evaluating optical purity. Analysis conditions (2) are analysis conditions for quantifying the generated Anti body with the (1S,2S) body of 1-ethoxycarbonyl-2-vinylcyclopropanecarboxylic acid as the main component and evaluating the generation ratio of Syn body to Anti body.

[0184] Analysis conditions (1)

[0185] Column: CHIRALPAK AD-3 (4.6×250 mm, manufactured by Daicel Chemical Co., Ltd.)

[0186] Eluent: hexane: ethanol: trifluoroacetic acid = 95:5:0.1

[0187] Flow rate: 0.8ml / min

[0188] Temperature: 30℃

[0189] Detection: UV 210nm

[0190] Analysis conditions (2)

[0191] Column: COSMOSIL 5C18-MS-II (4.6×250 mm, manufactured by Nacalai Tesque Co., Ltd.)

[0192] Eluent A: Aqueous solution containing 0.1% trifluoroacetophenone

[0193] Eluent B: Acetonitrile containing 0.1% trifluoroacetophenone

[0194] Flow rate: 0.8ml / min

[0195] Temperature: 40℃

[0196] Detection: UV 210nm

[0197] Table 1. Gradient elution program

[0198] minute Eluent A (%) Eluent B (%) 0 75 25 20 30 70 23 30 70 30 75 25

[0199] Table 1 shows the amount of Anti-form of 1-ethoxycarbonyl-2-vinylcyclopropanecarboxylic acid produced when each bacterial cell was used, the production ratio of Syn-form to Anti-form, and the optical purity.

[0200] Table 2.

[0201]

[0202] As shown in Table 2, compared with the existing hydrolase having the amino acid sequence of sequence number 8 (AFX20780) or sequence number 24 (PnbA3027-m26), the hydrolase of the present invention having the amino acid sequence of sequence number 2 (RsD32Est), sequence number 4 (PdEst) and sequence number 6 (McEst) produces a large amount of Anti-body of 1-ethoxycarbonyl-2-vinylcyclopropanecarboxylic acid, and the production ratio of Syn-body to Anti-body is low.

[0203] In particular, the amount of Anti-form of 1-ethoxycarbonyl-2-vinylcyclopropanecarboxylic acid produced by the hydrolase of the present invention having Sequence No. 2 (RsD32Est) was extremely large, Syn-form was not produced, and the optical purity was also extremely high.

[0204] in addition, Figure 1 This is the result of HPLC analysis of the reaction product obtained using the bacterial cell having the amino acid sequence RsD32Est. Figure 2 This is the result of HPLC analysis of the reaction product obtained using the bacterial cell having the amino acid sequence PnbA3027-m26. Figure 1 It is shown that the hydrolase of the present invention having the amino acid sequence RsD32Est hardly generates the (1S,2R)-, (1R,2S)- and (1R,2R)-forms of 1-ethoxycarbonyl-2-vinylcyclopropanecarboxylic acid, and can generate the (1S,2S)-form with high selectivity. Figure 2 This indicates that the existing hydrolase having the amino acid sequence PnbA3027-m26 produces a large amount of the (1S, 2R) form of 1-ethoxycarbonyl-2-vinylcyclopropanecarboxylic acid and has a lower selectivity than the hydrolase of the present invention.

[0205] Example 3: Preparation of (1S, 2S)-1-ethoxycarbonyl-2-vinylcyclopropanecarboxylic acid

[0206] In a 5L fermenter, 160mL of 1mol / L potassium phosphate buffer (pH 7.0), 1332mL of desalted water, 84.2g of diethyl 2-vinylcyclopropane-1,1-dicarboxylate, and 24g of wet cells of the E. coli clone BL21(DE3) / pJ411RsD32Est obtained in Example 1 were mixed, the reaction temperature was set to 30°C, the pH during the reaction was set to 7.0, and the reaction was allowed to proceed for 24 hours at a sufficient stirring speed. The concentration of (1S,2S)-1-ethoxycarbonyl-2-vinylcyclopropanecarboxylic acid at the end of the reaction was 22.3g / L.

[0207] After removing the bacterial cells and bacterial cell residues from 1100 mL of the liquid after the reaction (pure (1S,2S)-1-ethoxycarbonyl-2-vinylcyclopropanecarboxylic acid is 22.2 g), 500 mL of toluene was added, and after stirring at room temperature for 20 minutes, the toluene layer was separated to remove the residual 2-vinylcyclopropane-1,1-dicarboxylic acid diethyl ester. 6N (=3 mol / L) sulfuric acid was added to the obtained water layer to adjust the pH to 2.0. Then, 250 mL of toluene was added, and after stirring at room temperature for 20 minutes, a toluene layer containing (1S,2S)-1-ethoxycarbonyl-2-vinylcyclopropanecarboxylic acid was obtained. 250 mL of toluene was added to the obtained water layer again, and after stirring at room temperature for 20 minutes, a toluene layer containing (1S,2S)-1-ethoxycarbonyl-2-vinylcyclopropanecarboxylic acid was obtained. The purity and optical purity of the obtained toluene layer were analyzed by HPLC. As a result, the amount of pure (1S,2S)-1-ethoxycarbonyl-2-vinylcyclopropanecarboxylic acid was 19.3 g, and the optical purity was 99.7%ee.

[0208] Reference Example 1: Cloning of p-nitrobenzyl esterase gene (pnbA3027; SEQ ID NO: 9)

[0209] Gene cloning

[0210] Bacillus subtilis NBRC3027 was cultured overnight in a liquid culture medium designated by the strain depository, and chromosomal DNA was prepared from the obtained bacterial cells using DNeasy Blood and Tissue Kit (manufactured by Qiagen).

[0211] Primers for amplifying the full-length p-nitrobenzyl esterase gene were designed and synthesized based on the gene sequence (pnbA23857, sequence number 11) encoding p-nitrobenzyl esterase derived from the known strain Bacillus subtilis ATCC23857 (PNBE23857, GenBank accession number AQR87688, sequence number 12). The respective base sequences are shown in sequence numbers 13 (pnbA F) and 14 (pnbA R) in the sequence listing.

[0212] Using the prepared chromosomal DNA as a template and pnbA F and pnbA R as primers, a DNA fragment of about 1.5 kbp was amplified by PCR.

[0213] Preparation of expression vector

[0214] Plasmid pKV32 prepared according to the method described in Japanese Patent Application Laid-Open No. 2005-34025 was used as a template, and a fragment of about 4 kbp was amplified by PCR using primers shown in sequence number 15 (pKVXmaIFW) and primers shown in sequence number 16 (pKVXmaIRV). The amplified fragment was digested with XmaI and self-circulated using a Ligation-Convenience kit (manufactured by Nippon Gene Co., Ltd.), and the resulting plasmid was named pKW32.

[0215] Preparation of expression plasmid

[0216] The DNA fragment obtained by cloning the above gene was introduced into the cloning vector pKW32 prepared in the above "Preparation of expression vector" according to a conventional method. The obtained plasmid is hereinafter referred to as ppnbA3027.

[0217] The DNA sequence inserted into the plasmid was analyzed and confirmed to contain a gene consisting of an ORF of 1467 bp. The obtained gene was named pnbA3027, and the sequence is shown in SEQ ID NO: 9. The amino acid sequence encoded by the DNA sequence was named PNBE3027, and its amino acid sequence is shown in SEQ ID NO: 10. The amino acid sequence of PNBE3027 showed 90% sequence identity with respect to the known sequence of PNBE23857.

[0218] Reference Example 2: Modification of the p-nitrobenzyl esterase gene by mutation introduction

[0219] Using the plasmid ppnbA3027 obtained in Reference Example 1 as a template, using the primers (L70FW) shown in sequence number 17 and the primers (L70RV) shown in sequence number 18 in the sequence listing, random mutations were introduced at the base encoding leucine at amino acid number 70 using the QuikChange multi-point mutagenesis kit (manufactured by Stratagene). Similarly, using the primer (L313FW) shown in sequence number 19 and the primer (L313RV) shown in sequence number 20 of the sequence listing, random mutations were introduced into the base encoding the leucine residue of amino acid number 313, and using the primer (L270L273FW) shown in sequence number 21 and the primer (L270L273RV) shown in sequence number 22 of the sequence listing, random mutations were introduced into the bases encoding the leucine residues of amino acid numbers 270 and 273, and the obtained mutation-introduced plasmids were used to transform Escherichia coli JM109 (manufactured by Takara Bio Co., Ltd.) according to conventional methods.

[0220] Clone No. 26 was isolated from the obtained recombinant E. coli, and the DNA sequence inserted in the plasmid possessed by the clone was analyzed. The sequence thereof (named pnbA3027-26) was shown in SEQ ID NO: 23. The amino acid sequence encoded by the DNA sequence was named PNBE3027-m26, and the amino acid sequence thereof was shown in SEQ ID NO: 24.

[0221] Industrial Applicability

[0222] By using the hydrolase of the present invention, (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid having high optical purity can be produced industrially with high efficiency and low cost.

[0223] The present invention is based on Japanese Patent Application No. 2018-070188 filed in Japan, and all the contents thereof are included in this specification. Sequence Listing <110> API Corporation <120> Novel hydrolase and method for producing (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid using the same (Novel hydrolase and method for producing (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid by utilizng thereof) <130> 092851 <150> JP2018-070188 <151> 2018-03-30 <160> 24 <170> PatentIn version 3.5 <210> 1 <211> 1062 <212> DNA <213> Artificial Sequence <220> <223> Ecoli opt <400> 1 atgaatctgc caccgggtgt ccgctctgtt acgactcaaa cttcacgtct gcgcttgcat 60 cacttggagg ccggtccggt cgatggcgtg ccactggttc tggtgcacgg taatctgagc 120 tccggtcgtt tctatgaaga tgtgatgccg gccctcgcga aaacctatcg cgtcatcgca 180 ccggatatgc gcggtttcgg tgatagcgag cgcgttaccc tggatgcgac gcgcggtctg 240 gcggactggg cagatgacat tgcggcgctg ctggaagcgt tagacattga ccaggctccg 300 catctgctgg gctggagcac gggtgcaggc gcgattaccc gttacgtcct ggatggtcgt 360 accgccgctt cgctgacgtt gatggacccg gtcccgccgt acggtttcgt cggtatgcac 420 gcagacggca cgccgtggtt tagcgactat gcgggctgtg gtgctggtgt aatgaacacg 480 gaatttaccg agcgtattgc tgctggtgac cgttccaccg attccctggc atctccgcgt 540 aacgttgcgg caggcttttg gggtgaggcg ccgccgatca gccaagagcg tgttgacgtg 600 ctgattgacg agctgttgaa aacctgggtt agcgaagata atttccggg tagcgttgtg 660 ccgagcaaaa actggccggg tatcgcccct ggcaccaccg gcatcctgaa cgcactgagc 720 ccgaagtact gcgactggag ccgcatcacc gagctgggta gcaagccgcc gattatgtgg 780 atccagggtg gccaagatga tgtgatcagc aatgcgagcc acaacgaccc ggcgaccctg 840 ggcgcagcgg gcctgatccc gggttggccg ggcgaagatg tctgcccggc gcagccgatg 900 atcacccaga ttcgtgatgt gttgcaagca tacgaagatg ccggcggccg tacgcgtacc 960 gagtggttcg aggcaagcca ccatctgcct atgattgaag aaccggaccg ttggctgcaa 1020 gccgtgtcta gctttgtggc ggaagccgac gcgattgcgt aa 1062 <210> 2 <211> 353 <212> PRT <213> Rhodococcus sp. D32 <400> 2 Met Asn Leu Pro Pro Gly Val Arg Ser Val Thr Thr Gln Thr Ser Arg 1 5 10 15 Leu Arg Leu His His Leu Glu Ala Gly Pro Val Asp Gly Val Pro Leu 20 25 30 Val Leu Val His Gly Asn Leu Ser Ser Gly Arg Phe Tyr Glu Asp Val 35 40 45 Met Pro Ala Leu Ala Lys Thr Tyr Arg Val Ile Ala Pro Asp Met Arg 50 55 60 Gly Phe Gly Asp Ser Glu Arg Val Thr Leu Asp Ala Thr Arg Gly Leu 65 70 75 80 Ala Asp Trp Ala Asp Asp Ile Ala Ala Leu Leu Glu Ala Leu Asp Ile 85 90 95 Asp Gln Ala Pro His Leu Leu Gly Trp Ser Thr Gly Ala Gly Ala Ile 100 105 110 Thr Arg Tyr Val Leu Asp Gly Arg Thr Ala Ala Ser Leu Thr Leu Met 115 120 125 Asp Pro Val Pro Pro Tyr Gly Phe Val Gly Met His Ala Asp Gly Thr 130 135 140 Pro Trp Phe Ser Asp Tyr Ala Gly Cys Gly Ala Gly Val Met Asn Thr 145 150 155 160 Glu Phe Thr Glu Arg Ile Ala Ala Gly Asp Arg Ser Thr Asp Ser Leu 165 170 175 Ala Ser Pro Arg Asn Val Ala Ala Gly Phe Trp Gly Glu Ala Pro Pro 180 185 190 Ile Ser Gln Glu Arg Val Asp Val Leu Ile Asp Glu Leu Leu Lys Thr 195 200 205 Trp Val Ser Glu Asp Asn Phe Pro Gly Ser Val Val Pro Ser Lys Asn 210 215 220 Trp Pro Gly Ile Ala Pro Gly Thr Thr Gly Ile Leu Asn Ala Leu Ser 225 230 235 240 Pro Lys Tyr Cys Asp Trp Ser Arg Ile Thr Glu Leu Gly Ser Lys Pro 245 250 255 Pro Ile Met Trp Ile Gln Gly Gly Gln Asp Asp Val Ile Ser Asn Ala 260 265 270 Ser His Asn Asp Pro Ala Thr Leu Gly Ala Ala Gly Leu Ile Pro Gly 275 280 285 Trp Pro Gly Glu Asp Val Cys Pro Ala Gln Pro Met Ile Thr Gln Ile 290 295 300 Arg Asp Val Leu Gln Ala Tyr Glu Asp Ala Gly Gly Arg Thr Arg Thr 305 310 315 320 Glu Trp Phe Glu Ala Ser His His Leu Pro Met Ile Glu Glu Pro Asp 325 330 335 Arg Trp Leu Gln Ala Val Ser Ser Phe Val Ala Glu Ala Asp Ala Ile 340 345 350 Ala <210> 3 <211> 1053 <212> DNA <213> Artificial Sequence <220> <223> Ecoli opt <400> 3 atgcagctgt tgcctggtgt tcgtagcgtg gtggtcccaa ctgatcgtct ggaagttcat 60 ttggtggagt atggtcctga agagggcgtt ccggttgtga tgctgcacgg taacctttct 120 accggtcgtt tctttgagca cctgttcccg ggtgccccgc agggttaccg tatcatcgca 180 ccggacatgc gttgctttgg cgatacggaa cgtctgccgt tagacgcaac ccgtggcctg 240 gctgactggg ccgatgacgt tgcggctctg ctgcgtgcac tgcgcgttga gcgtccggtt 300 cacctcctgg gctggagcac tgcgggcgcg gccattgtgg attttgcaag cgcgcatccg 360 gtcacctctc tgaccttcct ggatccggtc agcccgtacg gtttcggtgg cgtgctggcg 420 gatggtacgc cgtgcttccc ggactttgcc ggttccggcg gcggcattgt gaatccagaa 480 gtcgtccgtc gcctggccga gggtgacgat acgaccgaga gcccgttttc tattcgcagc 540 gtcatgcgtg gctcgtattg gttggaaagc catagcgaac cgcgcgaaga tctgctggta 600 gcagaagtgc tgaaaaccgt gaccggcgac gacaattatc ctggtgactc cgtcgcgagc 660 ccgaattggc cgggtagcgc accgggtacg accggtatca tcaacgctct gagcccgaag 720 tactgtaact ggacgcgcgt tgttgacctg gatccgaaac cgccggtttt gtggacgcat 780 ggtgccgagg acaccgtcgt cgcggatgcg agcatgcaag acctgggtac cctgggcgag 840 ctgggttacg tgccgggctg gccgggtgca gatgtgttcc cgagccagcc gatggtgagc 900 caaattcgcg aagtcctggg ccgttacgcg gcggcgggtg gccacgttcg caccgagatc 960 ctgccgggtg cgggccactc cccgcacatt gagctgccag aactgtggag cggtgtgttt 1020 tgggacttcg ttggtgcggc ggagcgtggt taa 1053 <210> 4 <211> 350 <212> PRT <213> Pseusdonocardia dioxanivorans CB1190 <400> 4 Met Gln Leu Leu Pro Gly Val Arg Ser Val Val Val Pro Thr Asp Arg 1 5 10 15 Leu Glu Val His Leu Val Glu Tyr Gly Pro Glu Glu Gly Val Pro Val 20 25 30 Val Met Leu His Gly Asn Leu Ser Thr Gly Arg Phe Phe Glu His Leu 35 40 45 Phe Pro Gly Ala Pro Gln Gly Tyr Arg Ile Ile Ala Pro Asp Met Arg 50 55 60 Cys Phe Gly Asp Thr Glu Arg Leu Pro Leu Asp Ala Thr Arg Gly Leu 65 70 75 80 Ala Asp Trp Ala Asp Asp Val Ala Ala Leu Leu Arg Ala Leu Arg Val 85 90 95 Glu Arg Pro Val His Leu Leu Gly Trp Ser Thr Ala Gly Ala Ala Ile 100 105 110 Val Asp Phe Ala Ser Ala His Pro Val Thr Ser Leu Thr Phe Leu Asp 115 120 125 Pro Val Ser Pro Tyr Gly Phe Gly Gly Val Leu Ala Asp Gly Thr Pro 130 135 140 Cys Phe Pro Asp Phe Ala Gly Ser Gly Gly Gly Ile Val Asn Pro Glu 145 150 155 160 Val Val Arg Arg Leu Ala Glu Gly Asp Asp Thr Thr Glu Ser Pro Phe 165 170 175 Ser Ile Arg Ser Val Met Arg Gly Ser Tyr Trp Leu Glu Ser His Ser 180 185 190 Glu Pro Arg Glu Asp Leu Leu Val Ala Glu Val Leu Lys Thr Val Thr 195 200 205 Gly Asp Asp Asn Tyr Pro Gly Asp Ser Val Ala Ser Pro Asn Trp Pro 210 215 220 Gly Ser Ala Pro Gly Thr Thr Gly Ile Ile Asn Ala Leu Ser Pro Lys 225 230 235 240 Tyr Cys Asn Trp Thr Arg Val Val Asp Leu Asp Pro Lys Pro Pro Val 245 250 255 Leu Trp Thr His Gly Ala Glu Asp Thr Val Val Ala Asp Ala Ser Met 260 265 270 Gln Asp Leu Gly Thr Leu Gly Glu Leu Gly Tyr Val Pro Gly Trp Pro 275 280 285 Gly Ala Asp Val Phe Pro Ser Gln Pro Met Val Ser Gln Ile Arg Glu 290 295 300 Val Leu Gly Arg Tyr Ala Ala Ala Gly Gly His Val Arg Thr Glu Ile 305 310 315 320 Leu Pro Gly Ala Gly His Ser Pro His Ile Glu Leu Pro Glu Leu Trp 325 330 335 Ser Gly Val Phe Trp Asp Phe Val Gly Ala Ala Glu Arg Gly 340 345 350 <210> 5 <211> 1113 <212> DNA <213> Artificial Sequence <220> <223> Ecoli opt <400> 5 atgaccctgt ttgatggcat cacttcgcgt attgttgaca ccgatcgtct gaccgtgaat 60 attctggagc gtgcggcaga cgatccgcaa acgccgcctg atcgcacggt tgtttttgtg 120 catggtaacg tcagcagcgc gctgttttgg caagaaatta tgcaagacct cccgagcgat 180 ctgcgtgcta tcgcggtgga tctgcgtggc ttcggtggca gcgagcacgc accggtcgac 240 gcgacccgtg gtgttcgcga tttcagcgat gacttgcacg caacgctgga agcactggat 300 atcccggtcg cacacctggt cggttggagc atgggtggcg gcgtggttat gcagtatgca 360 ttagaccatc cggttttgag cctgacgctg cagtccccgg tcagcccgta cggtttcggt 420 ggcacccgtc gtgacggcag ccgtctgact gatgacgatg ctggctgcgg tggcggcggc 480 gccaatccgg atttcattca gcgtctgatc gaccacgaca cgtccgacga cgcgcagacc 540 agcccgcgct ccgttttccg tgcgggttac gtagcgagcg attacaccac ggaccacgaa 600 gatgtgtggg tggagagcat gctgaccacc tctaccgcgg acggcaatta cccaggtgac 660 gccgtcccga gcgacaactg gccaggtttt gccgcgggtc gccacggtgt tctgaacacg 720 atggcgcctc aatacttcga tgtcagcggt atcgttgatc tggcggagaa accgccgatt 780 ttgtggatcc atggtaccgc ggatgcgatt gtgtccgacg cgagctttta tgacctgaac 840 tatctgggtc agctgggtat cgtgccgggt tggccgggtg aagatgtcgc tccggcccaa 900 gaaatggtta gccagacgcg cgacgtcctg ggccgttacg ctgcgggtgg cggcaccgtt 960 accgaagttg ccgttgaggg tgcgggtcac agcgcacatt tggagcgtcc ggccgtgttc 1020 cgccacgcgc tgctggaaat tattggttat gtgggtgcgg ctgctgaccc ggcaccgccg 1080 actgaagcaa tcatcatccg ctctgccgac taa 1113 <210> 6 <211> 370 <212> PRT <213> Microbacterium chocolatum <400> 6 Met Thr Leu Phe Asp Gly Ile Thr Ser Arg Ile Val Asp Thr Asp Arg 1 5 10 15 Leu Thr Val Asn Ile Leu Glu Arg Ala Ala Asp Asp Pro Gln Thr Pro 20 25 30 Pro Asp Arg Thr Val Val Phe Val His Gly Asn Val Ser Ser Ala Leu 35 40 45 Phe Trp Gln Glu Ile Met Gln Asp Leu Pro Ser Asp Leu Arg Ala Ile 50 55 60 Ala Val Asp Leu Arg Gly Phe Gly Gly Ser Glu His Ala Pro Val Asp 65 70 75 80 Ala Thr Arg Gly Val Arg Asp Phe Ser Asp Asp Leu His Ala Thr Leu 85 90 95 Glu Ala Leu Asp Ile Pro Val Ala His Leu Val Gly Trp Ser Met Gly 100 105 110 Gly Gly Val Val Met Gln Tyr Ala Leu Asp His Pro Val Leu Ser Leu 115 120 125 Thr Leu Gln Ser Pro Val Ser Pro Tyr Gly Phe Gly Gly Thr Arg Arg 130 135 140 Asp Gly Ser Arg Leu Thr Asp Asp Asp Ala Gly Cys Gly Gly Gly Gly 145 150 155 160 Ala Asn Pro Asp Phe Ile Gln Arg Leu Ile Asp His Asp Thr Ser Asp 165 170 175 Asp Ala Gln Thr Ser Pro Arg Ser Val Phe Arg Ala Gly Tyr Val Ala 180 185 190 Ser Asp Tyr Thr Thr Asp His Glu Asp Val Trp Val Glu Ser Met Leu 195 200 205 Thr Thr Ser Thr Ala Asp Gly Asn Tyr Pro Gly Asp Ala Val Pro Ser 210 215 220 Asp Asn Trp Pro Gly Phe Ala Ala Gly Arg His Gly Val Leu Asn Thr 225 230 235 240 Met Ala Pro Gln Tyr Phe Asp Val Ser Gly Ile Val Asp Leu Ala Glu 245 250 255 Lys Pro Pro Ile Leu Trp Ile His Gly Thr Ala Asp Ala Ile Val Ser 260 265 270 Asp Ala Ser Phe Tyr Asp Leu Asn Tyr Leu Gly Gln Leu Gly Ile Val 275 280 285 Pro Gly Trp Pro Gly Glu Asp Val Ala Pro Ala Gln Glu Met Val Ser 290 295 300 Gln Thr Arg Asp Val Leu Gly Arg Tyr Ala Ala Gly Gly Gly Thr Val 305 310 315 320 Thr Glu Val Ala Val Glu Gly Ala Gly His Ser Ala His Leu Glu Arg 325 330 335 Pro Ala Val Phe Arg His Ala Leu Leu Glu Ile Ile Gly Tyr Val Gly 340 345 350 Ala Ala Ala Asp Pro Ala Pro Pro Thr Glu Ala Ile Ile Ile Arg Ser 355 360 365 Ala Asp 370 <210> 7 <211> 894 <212> DNA <213> Artificial Sequence <220> <223> Ecoli opt <400> 7 atggaaaagc gcagcattac tctgaaaaac ggtgaagttt acaaatacgt ggaacagggt 60 cagggcgacc aagttctgct gctgatccat ggcaacttta gctccagcct gcacttcacc 120 ccgttgctgg agcgcctgcc gaagaacatt aaggttattg cgccggactt gcgtggttat 180 ggtgattcat cttactatcg tcgtatcagc tctctgaacg acttcgcgga agatgtccac 240 atgtttatgg aagccaaaga aattaaaagc taccacgtag ttggctggag cctgggtggc 300 ggcgtggcgc tggaactggc ggcacatcat ccagaggctg tggagtcctt ggtgctcatc 360 aacagcacca cgcacaaggg ttatccggtg ttcaagaaag gtgcggatgg taagccactg 420 gtcggtgaag tctatcaaag cgccgatgag atggcaaatg atccggtcca agtcctgccg 480 ctgctgaagg ctcaaaaaga taagaatttt gactttgtta gctatatctt cgatgttacc 540 atttacaccg tgaataagcc ttcggtggat gacaacaagc tgtggattaa cgaaagcctg 600 aaacagcgta atctgccgga tgcagactgg gcgctggcga atttgaacat gagcgaccag 660 cacaatttct acaatgccgg tatgaacaat atctccaagg ttaaggcacc ggtgctgcac 720 acgtggggcg acaaagatat taccgtgccg gagtatatga tcaaagacaa tgtgaaagcg 780 ctggaagaac aaagcaaact ggtcgtctac gagaactgcg gccatagccc gctggttgat 840 gttccggacc agctgacgaa agacatcctg gactttatcg gttacaaggg ttaa 894 <210> 8 <211> 297 <212> PRT <213> Unknown <220> <223> patented sequence <400> 8 Met Glu Lys Arg Ser Ile Thr Leu Lys Asn Gly Glu Val Tyr Lys Tyr 1 5 10 15 Val Glu Gln Gly Gln Gly Asp Gln Val Leu Leu Leu Ile His Gly Asn 20 25 30 Phe Ser Ser Ser Leu His Phe Thr Pro Leu Leu Glu Arg Leu Pro Lys 35 40 45 Asn Ile Lys Val Ile Ala Pro Asp Leu Arg Gly Tyr Gly Asp Ser Ser 50 55 60 Tyr Tyr Arg Arg Ile Ser Ser Leu Asn Asp Phe Ala Glu Asp Val His 65 70 75 80 Met Phe Met Glu Ala Lys Glu Ile Lys Ser Tyr His Val Val Gly Trp 85 90 95 Ser Leu Gly Gly Gly Val Ala Leu Glu Leu Ala Ala His His Pro Glu 100 105 110 Ala Val Glu Ser Leu Val Leu Ile Asn Ser Thr Thr His Lys Gly Tyr 115 120 125 Pro Val Phe Lys Lys Gly Ala Asp Gly Lys Pro Leu Val Gly Glu Val 130 135 140 Tyr Gln Ser Ala Asp Glu Met Ala Asn Asp Pro Val Gln Val Leu Pro 145 150 155 160 Leu Leu Lys Ala Gln Lys Asp Lys Asn Phe Asp Phe Val Ser Tyr Ile 165 170 175 Phe Asp Val Thr Ile Tyr Thr Val Asn Lys Pro Ser Val Asp Asp Asn 180 185 190 Lys Leu Trp Ile Asn Glu Ser Leu Lys Gln Arg Asn Leu Pro Asp Ala 195 200 205 Asp Trp Ala Leu Ala Asn Leu Asn Met Ser Asp Gln His Asn Phe Tyr 210 215 220 Asn Ala Gly Met Asn Asn Ile Ser Lys Val Lys Ala Pro Val Leu His 225 230 235 240 Thr Trp Gly Asp Lys Asp Ile Thr Val Pro Glu Tyr Met Ile Lys Asp 245 250 255 Asn Val Lys Ala Leu Glu Glu Gln Ser Lys Leu Val Val Tyr Glu Asn 260 265 270 Cys Gly His Ser Pro Leu Val Asp Val Pro Asp Gln Leu Thr Lys Asp 275 280 285 Ile Leu Asp Phe Ile Gly Tyr Lys Gly 290 295 <210> 9 <211> 1470 <212> DNA <213> Bacillus subtilis NBRC3027 <400> 9 atgactcatc aaatagtaac gactcaatac ggcaaagtaa aaggcacaac agaaaatggc 60 gtacataaat ggaaaggcat cccctatgcc agaccgcctg tcgggccatt gcgttttaaa 120 gcaccggaac ctccggaagc gtgggagaac gaactggacg caacagcgta cggccctatt 180 tgcccgcagc cgtctgattt gctgtcactt tcgtataatg agctgccccg ccagtctgag 240 aattgcttgt atgtcaatgt atttgcgcct gatactccaa gtcaaaacct gcctgtcatg 300 gtgtggattc acggcggcgc tttttatctt ggagcgggca gtgagccatt attcgatggg 360 tcaagacttg cggcgcaggg agaagtcatt gtcgttacac tgaattatcg actggggccg 420 tttggatttt tacatttgtc ttcgtttgat gaggcgtatt ccgataacct tggtcttttg 480 gaccaagccg ccgcactgaa atgggtgcga gacaatatct cagcatttgg cggtgatccg 540 gataacgtaa cggtatttgg agaatccgct ggcggcatga gcattgccgc gctgctcgca 600 atgcctgcgg caaaaggcct gttccagaaa gcgatcatgg aaagcggcgc ttctagaaca 660 atgacaacag aaaaagcggc tagcactgca gcagcctttt tacaggtcct tgggattaac 720 gagagccaat tggacagact gcacactgta tctgcggaag atttgcttaa agcggccgat 780 aagcttcgga aagcagaaaa tgaaaatctc tttcagctgt tattccagcc cgcccttgat 840 ccgaaaacgc tgcctgctga accagaaaaa gcaatcgcag gaggtgctgc tgccgacatt ccgctgttaa tcggaacaaa ccgcgatgaa ggatatttat ttttcacccc ggactcagac gttcattctc aagaaacgtt taatgccgcg cttgagtatt tattggaaca gccgctggca aagaaagccg ccgatctgta tccgcgttca ctagaaagcc aaattcatat gatgactgat ttgttatttt ggcgcccggc cgtcgcctat gcctccgctc agtctcaata cgcgcctgta 1140 tggatgtacc gatttgattg gcactctgat aagccgccat acaataaggc gtttcacgca ttagagcttc cttttgtttt cggaaatctg gacgggttag aacgaatggc aaaagcagag gttacggatg aggtgaaacg gctttctcat accatacaat cagcatggat cacgtttgcc aaaacagga acccaagcac cgaagatgta aaatggccgg cgtatcatga agaaacaaga from ttttagattc together atcgaaaacg atcctgaatc tgaaaaaagg cagaagctat tcccttcaaa aggregate <210> 10 <211> 489 <212> PRT <213> Bacillus subtilis NBRC3027 <400> 10 Met Thr His Gln Ile Val Thr Thr Gln Tyr Gly Lys Val Lys Gly Thr 1 5 10 15 Thr Glu Asn Gly Val His Lys Trp Lys Gly Ile Pro Tyr Ala Arg Pro 20 25 30 Pro Val Gly Pro Leu Arg Phe Lys Ala Pro Glu Pro Pro Glu Ala Trp 35 40 45 Glu Asn Glu Leu Asp Ala Thr Ala Tyr Gly Pro Ile Cys Pro Gln Pro 50 55 60 Ser Asp Leu Leu Ser Leu Ser Tyr Asn Glu Leu Pro Arg Gln Ser Glu 65 70 75 80 Asn Cys Leu Tyr Val Asn Val Phe Ala Pro Asp Thr Pro Ser Gln Asn 85 90 95 Leu Pro Val Met Val Trp Ile His Gly Gly Ala Phe Tyr Leu Gly Ala 100 105 110 Gly Ser Glu Pro Leu Phe Asp Gly Ser Arg Leu Ala Ala Gln Gly Glu 115 120 125 Val Ile Val Val Thr Leu Asn Tyr Arg Leu Gly Pro Phe Gly Phe Leu 130 135 140 His Leu Ser Ser Phe Asp Glu Ala Tyr Ser Asp Asn Leu Gly Leu Leu 145 150 155 160 Asp Gln Ala Ala Ala Leu Lys Trp Val Arg Asp Asn Ile Ser Ala Phe 165 170 175 Gly Gly Asp Pro Asp Asn Val Thr Val Phe Gly Glu Ser Ala Gly Gly 180 185 190 Met Ser Ile Ala Ala Leu Leu Ala Met Pro Ala Ala Lys Gly Leu Phe 195 200 205 Gln Lys Ala Ile Met Glu Ser Gly Ala Ser Arg Thr Met Thr Thr Glu 210 215 220 Lys Ala Ala Ser Thr Ala Ala Ala Phe Leu Gln Val Leu Gly Ile Asn 225 230 235 240 Glu Ser Gln Leu Asp Arg Leu His Thr Val Ser Ala Glu Asp Leu Leu 245 250 255 Lys Ala Ala Asp Lys Leu Arg Lys Ala Glu Asn Glu Asn Leu Phe Gln 260 265 270 Leu Leu Phe Gln Pro Ala Leu Asp Pro Lys Thr Leu Pro Ala Glu Pro 275 280 285 Glu Lys Ala Ile Ala Gly Gly Ala Ala Ala Asp Ile Pro Leu Leu Ile 290 295 300 Gly Thr Asn Arg Asp Glu Gly Tyr Leu Phe Phe Thr Pro Asp Ser Asp 305 310 315 320 Val His Ser Gln Glu Thr Phe Asn Ala Ala Leu Glu Tyr Leu Leu Glu 325 330 335 Gln Pro Leu Ala Lys Lys Ala Ala Asp Leu Tyr Pro Arg Ser Leu Glu 340 345 350 Ser Gln Ile His Met Met Thr Asp Leu Leu Phe Trp Arg Pro Ala Val 355 360 365 Ala Tyr Ala Ser Ala Gln Ser Gln Tyr Ala Pro Val Trp Met Tyr Arg 370 375 380 Phe Asp Trp His Ser Asp Lys Pro Pro Tyr Asn Lys Ala Phe His Ala 385 390 395 400 Leu Glu Leu Pro Phe Val Phe Gly Asn Leu Asp Gly Leu Glu Arg Met 405 410 415 Ala Lys Ala Glu Val Thr Asp Glu Val Lys Arg Leu Ser His Thr Ile 420 425 430 Gln Ser Ala Trp Ile Thr Phe Ala Lys Thr Gly Asn Pro Ser Thr Glu 435 440 445 Asp Val Lys Trp Pro Ala Tyr His Glu Glu Thr Arg Gln Thr Leu Ile 450 455 460 Leu Asp Ser Glu Ile Thr Ile Glu Asn Asp Pro Glu Ser Glu Lys Arg 465,470,475,480 Gln Lys Leu Phe Pro Ser Lys Gly Glu 485 <210> 11 <211> 1470 <212> DNA <213> Bacillus subtilis ATCC23857 <400> 11 atgactcatc aatagtaac gactcaatac ggcaaagtaa aaggcacaac ggaaaacggc 60 gtacataagt ggaaaggcat cccctatgcc aagccgcctg tcggacaatg gcgttttaaa 120 gcacctgagc cgcctgaagt gtgggaagat gtgcttgatg ccacagcgta cggctctatt 180 tgcccgcagc cgtctgattt gctgtcactt tcgtatactg agctgccccg ccagtccgag 240 gattgcttgt atgtcaatgt atttgcgcct gacaccccaa gtaaaaatct tcctgtcatg 300 gtgtggattc acggaggcgc tttttatcta ggagcgggca gtgagccatt gtatgacgga 360 tcaaaacttg cggcacaggg agaagtcatt gtcgttacat tgaactatcg gctggggccg 420 tttggcttt tgcacttgtc ttcatttaat gaggcgtatt ctgataacct tgggctttta 480 gaccaagccg ccgcgctgaa atgggtgcga gagaatattt cagcgtttgg cggtgatccc 540 gataacgtaa cagtatttgg agaatccgcc ggcgggatga gcattgccgc gctgcttgct 600 atgcctgcgg caaaaggcct gttccagaaa gcaatcatgg aaagcggcgc ttctcgaacg 660 atgacgaaag aacaagcggc gagcacctcg gcagcctttt tacaggtcct tgggattaac 720 gagggccaac tggataaatt gcatacggtt tctgcggaag atttgctaaa agcggctgat 780 cagcttcgga ttgcagaaaa agaaaatatc tttcagctgt tcttccagcc cgcccttgat 840 ccgaaaacgc tgcctgaaga accagaaaaa gcgatcgcag aaggggctgc ttccggtatt 900 ccgctattaa ttggaacaac ccgtgatgaa ggatatttat ttttcacccc ggattcagac 960 gttcattctc aggaaacgct tgatgcagcg ctcgagtatt tactagggaa gccgctggca 1020 gagaaagttg ccgatttgta tccgcgttct ctggaaagcc aaattcatat gatgactgat 1080 ttattatttt ggcgccctgc cgtcgcctat gcatccgcac agtctcatta cgcccctgtc 1140 tggatgtaca ggttcgattg gcacccgaag aagccgccgt acaataaagc gtttcacgca 1200 ttagagcttc cttttgtctt tggaaatctg gacggattgg aacgaatggc aaaagcggag 1260 attacggatg aggtgaaaca gctttctcac acgatacaat cagcgtggat cacgttcgcc 1320 aaaacaggaa acccaagcac cgaagctgtg aattggcctg cgtatcatga agaaacgaga 1380 gagacgctga ttttagactc agagattacg atcgaaaacg atcccgaatc tgaaaaaaagg 1440 cagaagctat tcccttcaaa aggagaataa 1470 <210> 12 <211> 489 <212> PRT <213> Bacillus subtilis ATCC23857 <400> 12 Met Thr His Gln Ile Val Thr Thr Gln Tyr Gly Lys Val Lys Gly Thr 1 5 10 15 Thr Glu Asn Gly Val His Lys Trp Lys Gly Ile Pro Tyr Ala Lys Pro 20 25 30 Pro Val Gly Gln Trp Arg Phe Lys Ala Pro Glu Pro Pro Glu Val Trp 35 40 45 Glu Asp Val Leu Asp Ala Thr Ala Tyr Gly Ser Ile Cys Pro Gln Pro 50 55 60 Ser Asp Leu Leu Ser Leu Ser Tyr Thr Glu Leu Pro Arg Gln Ser Glu 65 70 75 80 Asp Cys Leu Tyr Val Asn Val Phe Ala Pro Asp Thr Pro Ser Lys Asn 85 90 95 Leu Pro Val Met Val Trp Ile His Gly Gly Ala Phe Tyr Leu Gly Ala 100 105 110 Gly Ser Glu Pro Leu Tyr Asp Gly Ser Lys Leu Ala Ala Gln Gly Glu 115 120 125 Val Ile Val Val Thr Leu Asn Tyr Arg Leu Gly Pro Phe Gly Phe Leu 130 135 140 His Leu Ser Ser Phe Asn Glu Ala Tyr Ser Asp Asn Leu Gly Leu Leu 145 150 155 160 Asp Gln Ala Ala Ala Leu Lys Trp Val Arg Glu Asn Ile Ser Ala Phe 165 170 175 Gly Gly Asp Pro Asp Asn Val Thr Val Phe Gly Glu Ser Ala Gly Gly 180 185 190 Met Ser Ile Ala Ala Leu Leu Ala Met Pro Ala Ala Lys Gly Leu Phe 195 200 205 Gln Lys Ala Ile Met Glu Ser Gly Ala Ser Arg Thr Met Thr Lys Glu 210 215 220 Gln Ala Ala Ser Thr Ser Ala Ala Phe Leu Gln Val Leu Gly Ile Asn 225 230 235 240 Glu Gly Gln Leu Asp Lys Leu His Thr Val Ser Ala Glu Asp Leu Leu 245 250 255 Lys Ala Ala Asp Gln Leu Arg Ile Ala Glu Lys Glu Asn Ile Phe Gln 260 265 270 Leu Phe Phe Gln Pro Ala Leu Asp Pro Lys Thr Leu Pro Glu Glu Pro 275 280 285 Glu Lys Ala Ile Ala Glu Gly Ala Ala Ser Gly Ile Pro Leu Leu Ile 290 295 300 Gly Thr Thr Arg Asp Glu Gly Tyr Leu Phe Phe Thr Pro Asp Ser Asp 305 310 315 320 Val His Ser Gln Glu Thr Leu Asp Ala Ala Leu Glu Tyr Leu Leu Gly 325 330 335 Lys Pro Leu Ala Glu Lys Val Ala Asp Leu Tyr Pro Arg Ser Leu Glu 340 345 350 Ser Gln Ile His Met Met Thr Asp Leu Leu Phe Trp Arg Pro Ala Val 355 360 365 Ala Tyr Ala Ser Ala Gln Ser His Tyr Ala Pro Val Trp Met Tyr Arg 370 375 380 Phe Asp Trp His Pro Lys Lys Pro Pro Tyr Asn Lys Ala Phe His Ala 385 390 395 400 Leu Glu Leu Pro Phe Val Phe Gly Asn Leu Asp Gly Leu Glu Arg Met 405 410 415 Ala Lys Ala Glu Ile Thr Asp Glu Val Lys Gln Leu Ser His Thr Ile 420 425 430 Gln Ser Ala Trp Ile Thr Phe Ala Lys Thr Gly Asn Pro Ser Thr Glu 435 440 445 Ala Val Asn Trp Pro Ala Tyr His Glu Glu Thr Arg Glu Thr Leu Ile 450 455 460 Leu Asp Ser Glu Ile Thr Ile Glu Asn Asp Pro Glu Ser Glu Lys Arg 465 470 475 480 Gln Lys Leu Phe Pro Ser Lys Gly Glu 485 <210> 13 <211> 33 <212> DNA <213> Artificial sequence <220> <223> Primer <400> 13 gcgaattcat gactcatcaa atagtaacga ctc 33 <210> 14 <211> 33 <212> DNA <213> Artificial sequence <220> <223> Primers <400> 14 gctctagatt attctccttt tgaagggaat agc 33 <210> 15 <211> 32 <212> DNA <213> Artificial sequence <220> <223> Primers <400> 15 tccccccggg tcaaggcgca ctcccgttct gg 32 <210> 16 <211> 35 <212> DNA <213> Artificial sequence <220> <223> Primers <400> 16 tccccccggg tggggtgcct aatgagtgag ctaac 35 <210> 17 <211> 40 <212> DNA <213> Artificial sequence <220> <223> Primers <220> <221> misc_feature <222> (19)..(20) <223> n is a, c, g, or t <400> 17 ccgtctgatt tgctgtcann ktcgtataat gagctgcccc 40 <210> 18 <211> 40 <212> DNA <213> Artificial sequence <220> <223> Primers <220> <221> misc_feature <222> (21)..(22) <223> n is a, c, g, or t <400> 18 ggggcagctc attatacgam nntgacagca aatcagacgg 40 <210> 19 <211> 32 <212> DNA <213> Artificial sequence <220> <223> Primers <220> <221> misc_feature <222> (17)..(18) <223> n is a, c, g, or t <400> 19 ccgcgatgaa ggatatnnktttttcacccc gg 32 <210> 20 <211> 32 <212> DNA <213> Artificial sequence <220> <223> Primers <220> <221> misc_feature <222> (15)..(16) <223> n is a, c, g, or t <400> 20 ccggggtgaa aaamnnatat ccttcatcgc gg 32 <210> twenty one <211> 53 <212> DNA <213> Artificial sequence <220> <223> Primers <220> <221> misc_feature <222> (26)..(27) <223> n is a, c, g, or t <220> <221> misc_feature <222> (35)..(36) <223> n is a, c, g, or t <400> 21 gcttcggaaa gcagaaaatg aaaatnnktt tcagnnktta ttccagcccg ccc 53 <210> 22 <211> 53 <212> DNA <213> Artificial sequence <220> <223> Primer <220> <221> misc_feature <222> (18)..(19) <223> n is a, c, g, or t <220> <221> misc_feature <222> (27)..(28) <223> n is a, c, g, or t <400> 22 gggcgggctg gaataamnnc tgaaamnnat tttcattttc tgctttccga agc 53 <210> 23 <211> 1470 <212> DNA <213> Bacillus subtilis NBRC3027 <400> 23 atgactcatc aaatagtaac gactcaatac ggcaaagtaa aaggcacaac agaaaatggc 60 gtacataaat ggaaaggcat cccctatgcc agaccgcctg tcgggccatt gcgttttaaa 120 gcaccggagc ctccggaagc gtgggagaac gaactggacg caacagcgta cggccctatt 180 tgcccgcagc cgtctgattt gctgtcagat tcgtataatg agctgccccg ccagtctgag 240 aattgcttgt atgtcaatgt atttgcgcct gatactccaa gtcaaaacct gcctgtcatg 300 gtgtggattc acggcggcgc tttttatctt ggagcgggca gtgagccatt attcgatggg 360 tcaagacttg cggcgcaggg agaagtcatt gtcgttacac tgaattatcg actggggccg 420 tttggatttt tacatttgtc ttcgtttgat gaggcgtatt ccgataacct tggtcttttg 480 gaccaagccg ccgcactgaa atgggtgcga gacaatatct cagcatttgg cggtgatccg 540 gataacgtaa cggtatttgg agaatccgct ggcggcatga gcattgccgc gctgctcgca 600 atgcctgcgg caaaaggcct gttccagaaa gcgatcatgg aaagcggcgc ttctagaaca 660 atgacaacag aaaaagcggc tagcactgca gcagcctttt tacaggtcct tgggattaac 720 gagagccaat tggacagact gcacactgta tctgcggaag atttgcttaa agcggccgat 780 aagcttcgga aagcagaaaa tgaaaatcag tttcagcggt tattccagcc cgcccttgat 840 ccgaaaacgc tgcctgctga accagaaaaa gcaatcgcag gaggtgctgc tgccgacatt 900 ccgctgttaa tcggaacaaa ccgcgatgaa ggatatatgt ttttcacccc ggactcagac 960 gttcattctc aagaaacgtt taatgccgcg cttgagtatt tattggaaca gccgctggca 1020 aagaaagccg ccgatctgta tccgcgttca ctagaaagcc aaattcatat gatgactgat 1080 ttgtttttt ggcgcccggc cgtcgcctat gcctccgctc agtctcaata cgcgcctgta 1140 tggatgtacc gatttgattg gcactctgat aagccgccat acaataaggc gtttcacgca 1200 ttagagcttc cttttgtttt cggaaatctg gacgggttag aacgaatggc aaaagcagag 1260 gttacggatg aggtgaaacg gctttctcat accatacaat cagcatggat cacgtttgcc 1320 aaaacaggaa acccaagcac cgaagatgta aaatggccgg cgtatcatga agaaacaaga 1380 cagacgctga ttttagattc agagattacg atcgaaaacg atcctgaatc tgaaaaaaagg 1440 cagaagctat tcccttcaaa aggagaataa 1470 <210> 24 <211> 489 <212> PRT <213> Bacillus subtilis NBRC3027 <400> 24 Met Thr His Gln Ile Val Thr Thr Gln Tyr Gly Lys Val Lys Gly Thr 1 5 10 15 Thr Glu Asn Gly Val His Lys Trp Lys Gly Ile Pro Tyr Ala Arg Pro 20 25 30 Pro Val Gly Pro Leu Arg Phe Lys Ala Pro Glu Pro Pro Glu Ala Trp 35 40 45 Glu Asn Glu Leu Asp Ala Thr Ala Tyr Gly Pro Ile Cys Pro Gln Pro 50 55 60 Ser Asp Leu Leu Ser Asp Ser Tyr Asn Glu Leu Pro Arg Gln Ser Glu 65 70 75 80 Asn Cys Leu Tyr Val Asn Val Phe Ala Pro Asp Thr Pro Ser Gln Asn 85 90 95 Leu Pro Val Met Val Trp Ile His Gly Gly Ala Phe Tyr Leu Gly Ala 100 105 110 Gly Ser Glu Pro Leu Phe Asp Gly Ser Arg Leu Ala Ala Gln Gly Glu 115 120 125 Val Ile Val Val Thr Leu Asn Tyr Arg Leu Gly Pro Phe Gly Phe Leu 130 135 140 His Leu Ser Ser Phe Asp Glu Ala Tyr Ser Asp Asn Leu Gly Leu Leu 145 150 155 160 Asp Gln Ala Ala Ala Leu Lys Trp Val Arg Asp Asn Ile Ser Ala Phe 165 170 175 Gly Gly Asp Pro Asp Asn Val Thr Val Phe Gly Glu Ser Ala Gly Gly 180 185 190 Met Ser Ile Ala Ala Leu Leu Ala Met Pro Ala Ala Lys Gly Leu Phe 195 200 205 Gln Lys Ala Ile Met Glu Ser Gly Ala Ser Arg Thr Met Thr Thr Glu 210 215 220 Lys Ala Ala Ser Thr Ala Ala Ala Phe Leu Gln Val Leu Gly Ile Asn 225 230 235 240 Glu Ser Gln Leu Asp Arg Leu His Thr Val Ser Ala Glu Asp Leu Leu 245 250 255 Lys Ala Ala Asp Lys Leu Arg Lys Ala Glu Asn Glu Asn Gln Phe Gln 260 265 270 Arg Leu Phe Gln Pro Ala Leu Asp Pro Lys Thr Leu Pro Ala Glu Pro 275 280 285 Glu Lys Ala Ile Ala Gly Gly Ala Ala Ala Asp Ile Pro Leu Leu Ile 290 295 300 Gly Thr Asn Arg Asp Glu Gly Tyr Met Phe Phe Thr Pro Asp Ser Asp 305 310 315 320 Val His Ser Gln Glu Thr Phe Asn Ala Ala Leu Glu Tyr Leu Leu Glu 325 330 335 Gln Pro Leu Ala Lys Lys Ala Ala Asp Leu Tyr Pro Arg Ser Leu Glu 340 345 350 Ser Gln Ile His Met Met Thr Asp Leu Leu Phe Trp Arg Pro Ala Val 355 360 365 Ala Tyr Ala Ser Ala Gln Ser Gln Tyr Ala Pro Val Trp Met Tyr Arg 370 375 380 Phe Asp Trp His Ser Asp Lys Pro Pro Tyr Asn Lys Ala Phe His Ala 385 390 395 400 Leu Glu Leu Pro Phe Val Phe Gly Asn Leu Asp Gly Leu Glu Arg Met 405 410 415 Ala Lys Ala Glu Val Thr Asp Glu Val Lys Arg Leu Ser His Thr Ile 420 425 430 Gln Ser Ala Trp Ile Thr Phe Ala Lys Thr Gly Asn Pro Ser Thr Glu 435 440 445 Asp Val Lys Trp Pro Ala Tyr His Glu Glu Thr Arg Gln Thr Leu Ile 450 455 460 Leu Asp Ser Glu Ile Thr Ile Glu Asn Asp Pro Glu Ser Glu Lys Arg 465 470 475 480 Gln Lys Leu Phe Pro Ser Lys Gly Glu 485

Claims

1. A hydrolase, which is a polypeptide consisting of the amino acid sequence represented by SEQ ID NO:

2. A nucleic acid encoding the hydrolase according to claim 1 .

3. A method for producing (1S, 2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid, comprising: The hydrolase according to claim 1, a microorganism or cell capable of producing the enzyme, a treated product of the microorganism or cell containing the enzyme, and / or a culture solution containing the enzyme obtained by culturing the microorganism or cell is contacted with a 2-vinylcyclopropane-1,1-dicarboxylic acid dialkyl ester represented by formula (I), thereby producing a (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropanecarboxylic acid represented by formula (II), In formula (1), R is ethyl.

4. The manufacturing method according to claim 3, wherein: The microorganism or cell is a microorganism or cell transformed with the nucleic acid according to claim 2. A recombinant vector comprising the nucleic acid according to claim 2.

6. A transformant, characterized in that: Comprising the recombinant vector according to claim 5.